Cigna (CI) 10-Q5 May 232023 Q1 Quarterly reportFinancial data

Company Profile

Cover Page

Cover Page - shares	3 Months Ended
Cover Page - shares	Mar. 31, 2023	Apr. 28, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	001-38769
Entity Registrant Name	The Cigna Group
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-4991898
Entity Address, Address Line One	900 Cottage Grove Road
Entity Address, City or Town	Bloomfield
Entity Address, State or Province	CT
Entity Address, Postal Zip Code	06002
City Area Code	860
Local Phone Number	226-6000
Title of 12(b) Security	Common Stock, Par Value $0.01
Trading Symbol	CI
Security Exchange Name	NYSE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		295,872,231
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Central Index Key	0001739940

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	[1]
Revenues
Premiums	$ 11,025	$ 10,356
Net investment income	277	414
TOTAL REVENUES	46,517	44,006
Benefits and expenses
Pharmacy and other service costs	31,459	29,813
Medical costs and other benefit expenses	9,046	8,272
Selling, general and administrative expenses	3,538	3,275
Amortization of acquired intangible assets	459	458
TOTAL BENEFITS AND EXPENSES	44,502	41,818
Income from operations	2,015	2,188
Interest expense and other	(358)	(299)
Net realized investment losses	(56)	(322)
Income before income taxes	1,601	1,567
TOTAL INCOME TAXES	295	355
Net income	1,306	1,212
Less: Net income attributable to noncontrolling interests	39	15
SHAREHOLDERS' NET INCOME	$ 1,267	$ 1,197
Shareholders' net income per share
Basic (in dollars per share)	$ 4.28	$ 3.76
Diluted (in dollars per share)	$ 4.24	$ 3.73
Pharmacy revenues
Revenues
Revenues	$ 32,144	$ 30,697
Fees and other revenues
Revenues
Revenues	$ 3,071	$ 2,539

[1]Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Statement of Comprehensive Income [Abstract]
Net income	$ 1,306	$ 1,212	[1]
Other comprehensive income (loss), net of tax
Net unrealized appreciation (depreciation) on securities and derivatives	194	(843)	[2]
Net long-duration insurance and contractholder liabilities measurement adjustments	(331)	459	[2]
Net translation gains (losses) on foreign currencies	16	(63)	[2]
Postretirement benefits liability adjustment	10	13	[2]
Other comprehensive loss, net of tax	(111)	(434)	[2]
Total comprehensive income	1,195	778	[2]
Comprehensive income (loss) attributable to noncontrolling interests
Net income attributable to redeemable noncontrolling interests	34	3	[2]
Net income attributable to other noncontrolling interests	5	12	[2]
Other comprehensive loss attributable to redeemable noncontrolling interests	0	(2)	[2]
Total comprehensive income attributable to noncontrolling interests	39	13	[2]
SHAREHOLDERS' COMPREHENSIVE INCOME	$ 1,156	$ 765	[2]

[1]Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.[2]Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions		Mar. 31, 2023	Dec. 31, 2022	[1]
Assets
Cash and cash equivalents		$ 7,935	$ 5,924
Investments		914	905
Accounts receivable, net		17,704	17,218
Inventories		4,211	4,777
Other current assets		1,263	1,298
Total current assets		32,027	30,122
Long-term investments		19,010	16,288
Reinsurance recoverables		5,286	5,416
Property and equipment		3,837	3,774
Goodwill		45,811	45,811
Other intangible assets		32,102	32,492
Other assets		2,563	2,704
Separate account assets		7,340	7,278
TOTAL ASSETS		147,976	143,885
Liabilities
Current insurance and contractholder liabilities		7,166	5,409
Pharmacy and other service costs payable		17,609	17,070
Accounts payable		7,360	7,775
Accrued expenses and other liabilities		9,174	7,978
Short-term debt		3,418	2,993
Total current liabilities		44,727	41,225
Non-current insurance and contractholder liabilities		11,790	11,976
Deferred tax liabilities, net		7,707	7,786
Other non-current liabilities		2,692	2,766
Long-term debt		29,124	28,100
Separate account liabilities		7,340	7,278
TOTAL LIABILITIES		103,380	99,131
Contingencies — Note 16
Redeemable noncontrolling interests		78	66
Shareholders' equity
Common stock	[2]	4	4
Additional paid-in capital		30,332	30,233
Accumulated other comprehensive loss		(1,769)	(1,658)
Retained earnings		38,841	37,940
Less: Treasury stock, at cost		(22,906)	(21,844)
TOTAL SHAREHOLDERS' EQUITY		44,502	44,675
Other noncontrolling interests		16	13
Total equity		44,518	44,688	[3]
Total liabilities and equity		$ 147,976	$ 143,885

[1]Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.[2]Par value per share, $0.01; shares issued, 399 million as of March 31, 2023 and 398 million as of December 31, 2022; authorized shares, 600 million.[3]Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements to the Consolidated Financial Statements for further information.

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares issued (in shares)	399,000,000	398,000,000
Common stock, shares authorized (in shares)	600,000,000	600,000,000

Consolidated Statements of Chan

Consolidated Statements of Changes in Total Equity - USD ($) $ in Millions		Total		Shareholders' Equity	Common Stock	Additional Paid-in Capital	Accumulated Other Comprehensive (Loss)	Retained Earnings	Treasury Stock	Other Non- controlling Interests
Balance at Dec. 31, 2021	[1]	$ 46,976		$ 46,958	$ 4	$ 29,574	$ (1,068)	$ 32,623	$ (14,175)	$ 18
Changes in Total Equity [Roll Forward]
Effect of issuing stock for employee benefit plans		90		90		162			(72)
Other comprehensive income (loss)		(432)		(432)			(432)
Net income		1,209		1,197				1,197		12
Common dividends declared		(356)		(356)				(356)
Repurchase of common stock		(1,334)		(1,334)		0			(1,334)
Other transactions impacting noncontrolling interests		(8)		0		0				(8)
Balance at Mar. 31, 2022		46,145		46,123	4	29,736	(1,500)	33,464	(15,581)	22
Balance at Dec. 31, 2021	[1]	54
Change in Redeemable Noncontrolling Interests
Other comprehensive loss	[2]	(2)
Net income		3
Other transactions impacting noncontrolling interests		0
Balance at Mar. 31, 2022		55
Balance at Dec. 31, 2022	[1]	44,688	[3]	44,675	4	30,233	(1,658)	37,940	(21,844)	13
Changes in Total Equity [Roll Forward]
Effect of issuing stock for employee benefit plans		(5)		(5)		99			(104)
Other comprehensive income (loss)		(111)		(111)			(111)
Net income		1,272		1,267				1,267		5
Common dividends declared		(366)		(366)				(366)
Repurchase of common stock		(958)		(958)					(958)
Other transactions impacting noncontrolling interests		(2)		0						(2)
Balance at Mar. 31, 2023		44,518		$ 44,502	$ 4	$ 30,332	$ (1,769)	$ 38,841	$ (22,906)	$ 16
Balance at Dec. 31, 2022	[1]	66
Change in Redeemable Noncontrolling Interests
Other comprehensive loss		0
Net income		34
Other transactions impacting noncontrolling interests		(22)
Balance at Mar. 31, 2023		$ 78

[1]Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements to the Consolidated Financial Statements for further information.[2]Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.[3]Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Total Equity (Parenthetical) - $ / shares	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022
Statement of Stockholders' Equity [Abstract]
Common dividends declared (in dollars per share)	$ 1.23	$ 1.12	$ 1.12	$ 1.12	$ 1.12

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2023	Mar. 31, 2022
Cash Flows from Operating Activities
Net income		$ 1,306	$ 1,212	[1]
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		749	717	[2]
Realized investment losses, net		56	322	[1]
Deferred income tax benefit		(108)	(134)	[2]
Net changes in assets and liabilities, net of non-operating effects:
Accounts receivable, net		(479)	(983)	[2]
Inventories		566	222	[2]
Reinsurance recoverable and Other assets		72	584	[2]
Insurance liabilities		1,533	142	[2]
Pharmacy and other service costs payable		539	(74)	[2]
Accounts payable and Accrued expenses and other liabilities		690	85	[2]
Other, net		104	(63)	[2]
NET CASH PROVIDED BY OPERATING ACTIVITIES		5,028	2,030	[2]
Proceeds from investments sold:
Debt securities and equity securities		196	757	[2]
Investment maturities and repayments:
Debt securities and equity securities		257	456	[2]
Commercial mortgage loans		4	65	[2]
Other sales, maturities and repayments (primarily short-term and other long-term investments)		160	479	[2]
Investments purchased or originated:
Debt securities and equity securities		(2,794)	(1,246)	[2]
Commercial mortgage loans		0	(59)	[2]
Other (primarily short-term and other long-term investments)		(377)	(425)	[2]
Property and equipment purchases, net		(408)	(288)	[2]
Divestitures, net of cash sold		22	(57)	[2]
Other, net		(43)	(6)	[2]
NET CASH USED IN INVESTING ACTIVITIES		(2,983)	(324)	[2]
Cash Flows from Financing Activities
Deposits and interest credited to contractholder deposit funds		45	43	[2]
Withdrawals and benefit payments from contractholder deposit funds		(48)	(49)	[2]
Net change in short-term debt		(9)	(463)	[2]
Repayment of long-term debt		(80)	0	[2]
Net proceeds on issuance of long-term debt		1,491	0	[2]
Repurchase of common stock		(962)	(1,368)	[2]
Issuance of common stock		30	93	[2]
Common stock dividend paid		(368)	(357)	[2]
Other, net		(136)	(70)	[2]
NET CASH USED IN FINANCING ACTIVITIES		(37)	(2,171)	[2]
Effect of foreign currency rate changes on cash, cash equivalents and restricted cash		5	(23)	[2]
Net increase (decrease) in cash, cash equivalents and restricted cash		2,013	(488)	[2]
Cash, cash equivalents and restricted cash January 1, including held for sale assets	[2],[3]		5,548
Cash, cash equivalents and restricted cash December 31, including held for sale assets	[2]		5,060
Cash and cash equivalents reclassified to Assets of businesses held for sale		0	(591)	[2]
Cash, cash equivalents and restricted cash and cash equivalents January 1,	[3]	5,976
Cash, cash equivalents and restricted cash and cash equivalents December 31,	[4]	7,989	4,469	[2]
Supplemental Disclosure of Cash Information:
Income taxes paid, net of refunds		77	43	[2]
Interest paid		$ 322	$ 308	[2]

[1]Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.[2]Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.[3]Includes $425 million reported in Assets of businesses held for sale as of January 1, 2022.[4]Restricted cash and cash equivalents were reported in other long-term investments.

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022
Statement of Cash Flows [Abstract]
Cash, cash equivalents and restricted cash, reported in Assets of businesses held for sale	$ 0	$ 425	$ 591	[1]

[1]Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.

Description of Business

Description of Business	3 Months Ended
Description of Business	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Note 1 – Description of Business The Cigna Group, together with its subsidiaries (either individually or collectively referred to as the "Company", "we," "us" or "our"), is a global health company with a mission of helping those we serve improve their health and vitality. Our subsidiaries offer a differentiated set of pharmacy, medical, behavioral, dental and related products and services. The majority of these products are offered through employers and other groups such as governmental and non-governmental organizations, unions and associations. Cigna Healthcare also offers commercial health and dental insurance and Medicare products to individuals in the United States and selected international markets. In addition to these ongoing operations, The Cigna Group also has certain run-off operations. A full description of our segments follows: Evernorth Health Services includes a broad range of coordinated and point solution health services and capabilities, as well as those from partners across the health care system, in Pharmacy Benefits, Home Delivery Pharmacy, Specialty Pharmacy, Distribution and Care Delivery and Management Solutions, which are provided to health plans, employers, government organizations and health care providers. Cigna Healthcare includes the U.S. Commercial, U.S. Government and International Health operating segments which provide comprehensive medical and coordinated solutions to clients and customers. U.S. Commercial products and services include medical, pharmacy, behavioral health, dental and other products and services for insured and self-insured clients. U.S. Government solutions include Medicare Advantage, Medicare Supplement and Medicare Part D plans for seniors and individual health insurance plans. International Health solutions include health care coverage in our international markets, as well as health care benefits for globally mobile individuals and employees of multinational organizations. Other Operations comprises the remainder of our business operations, which includes ongoing businesses and exited businesses. Our ongoing businesses include continuing business (corporate-owned life insurance ("COLI")) and our run-off businesses. Our run-off businesses include (i) variable annuity reinsurance business (also referred to as "guaranteed minimum death benefit ("GMDB") and guaranteed minimum income benefit ("GMIB") business) that was effectively exited through reinsurance with Berkshire Hathaway Life Insurance Company of Nebraska ("Berkshire") in 2013, (ii) settlement annuity business, and (iii) individual life insurance and annuity and retirement benefits businesses comprised of deferred gains from the sales of these businesses. Our exited businesses include our interest in a joint venture in Türkiye, which was sold in December 2022 and the international life, accident and supplemental benefits businesses sold in July 2022 (the "Chubb transaction"). Corporate reflects amounts not allocated to operating segments, including net interest expense (defined as interest on corporate debt less net investment income on investments not supporting segment and other operations), certain litigation matters, expense associated with our frozen pension plans, charitable contributions, operating severance, certain overhead and enterprise-wide project costs and intersegment eliminations for products and services sold between segments.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
Summary of Significant Accounting Policies	Mar. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Basis of Presentation The Consolidated Financial Statements include the accounts of The Cigna Group and its consolidated subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. These Consolidated Financial Statements were prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"). Certain amounts in prior years have been reclassified to conform to the current year presentation. Amounts recorded in the Consolidated Financial Statements necessarily reflect management's estimates and assumptions about medical costs, investment and receivable valuations, interest rates and other factors. Significant estimates are discussed throughout these Notes; however, actual results could differ from those estimates. The impact of a change in estimate is generally included in earnings in the period of adjustment. Recent Accounting Pronouncements The Company's 2022 Form 10-K includes discussion of significant recent accounting pronouncements that either have impacted or may impact our financial statements in the future. The following information provides updates on recently adopted accounting pronouncements that have occurred since the Company filed its 2022 Form 10-K. There are no accounting pronouncements not yet adopted as of March 31, 2023. Targeted Improvements to the Accounting for Long-Duration Contracts ("LDTI"), Accounting Standards Update ("ASU") 2018-12 and related amendments The Cigna Group adopted LDTI January 1, 2023, which includes the following key provisions: • Changes to the measurement of the future policy benefits liability for traditional and limited-pay insurance contracts: • Assumptions used to measure cash flows (such as mortality, morbidity and lapse assumptions) are updated at least annually with the effect of changes in those assumptions remeasured retrospectively and reflected in current period net income. • Discount rate assumptions are updated quarterly based on market-level yields for low credit risk fixed income instruments ("upper-medium grade fixed-income instrument"), with any changes reflected in other comprehensive income. The upper-medium grade fixed-income instrument yield is interpreted to mean A-rated. • Deferred policy acquisition costs ("DAC") related to long-duration insurance contracts are amortized on a constant-level basis over the expected term of the related contracts. Other related deferred or capitalized balances (such as unearned revenue liability and value of business acquired) may use this simplified amortization method. • Market risk benefits ("MRB"), defined as protecting the contractholder from other-than-nominal capital market risk and exposing the insurer to that risk, are measured at fair value, with changes in fair value recognized in net income each period, except for the effect of the Company's change in nonperformance risk (own credit risk), which is recognized in other comprehensive income. • Additional disclosures, including disaggregated roll forwards for the liability for future policy benefits, market risk benefits, separate account liabilities and DAC, as well as information about significant inputs, judgments, assumptions and methods used in measurement. • The transition methods applied at adoption were: • The liability for future policy benefits was remeasured using a modified retrospective approach applied to all outstanding contracts as of the beginning of the earliest period presented and was recognized in the opening balance of retained earnings. The impact of remeasuring the future policy benefits liability for the discount rate was recorded through accumulated other comprehensive income. • DAC followed the transition method used for future policyholder benefits. • Market risk benefits were remeasured at fair value at the beginning of the earliest period presented. The difference between this fair value and carrying value was recognized in the opening balance of retained earnings, excluding the effect of the Company's change in nonperformance risk (own credit risk), which is recognized in accumulated other comprehensive income. Effects of adoption: • The new guidance applies to our long-duration insurance products predominantly within the Cigna Healthcare segment and Other Operations. • The cumulative effects of adopting the new standard were immaterial. The impacts were a decrease to January 1, 2021 Shareholders' equity of $139 million and an increase to Shareholders' net income for the year ended December 31, 2022 and December 31, 2021 of $36 million and $5 million, respectively. The corresponding impact to diluted earnings per share was an increase of $0.11 and $0.02 for the year ended December 31, 2022 and December 31, 2021, respectively. • The prior periods within our Consolidated Statements of Income, Consolidated Statements of Comprehensive Income, Consolidated Balance Sheets, Consolidated Statements of Changes in Total Equity and Consolidated Statements of Cash Flows were restated to conform to the current presentation. • Prior period balances in the Company's footnote disclosures have been updated to reflect adjustments resulting from the adoption of this standard. Refer to Note 9 to the Consolidated Financial Statements for the Company's updated accounting policies. • It is possible that our income recognition pattern could change on a prospective basis for several reasons: • Applying periodic assumption updates, versus the locked-in model, may change our timing of profit or loss recognition. • DAC amortization is on a constant level basis over the expected term of the related contracts and no longer tied to the emergence of profit on such contracts. Additionally, in December 2022, the Financial Accounting Standards Board ("FASB") published ASU 2022-05, which simplified the retrospective adoption of LDTI by permitting companies to make an accounting policy election to exclude contracts that are sold and removed from the balance sheet prior to the effective date of the standard from the retrospective adoption of LDTI. The Cigna Group made this policy election for the contracts sold in the Chubb transaction and our divested interest in a joint venture in Türkiye.

Accounts Receivable, Net

Accounts Receivable, Net	3 Months Ended
Accounts Receivable, Net	Mar. 31, 2023
Receivables [Abstract]
Accounts Receivable, Net	Note 3 – Accounts Receivable, Net The following amounts were included within Accounts receivable, net: (In millions) March 31, 2023 December 31, 2022 Noninsurance customer receivables $ 7,845 $ 6,899 Pharmaceutical manufacturers receivables 7,128 7,108 Insurance customer receivables 2,467 2,963 Other receivables 264 248 Total $ 17,704 $ 17,218

Supplier Finance Program

Supplier Finance Program	3 Months Ended
Supplier Finance Program	Mar. 31, 2023
Payables and Accruals [Abstract]
Supplier Finance Program	Note 4 – Supplier Finance ProgramThe Company facilitates a voluntary supplier finance program (the "program") that provides suppliers the opportunity to sell their receivables due from us (i.e., our payment obligations to the suppliers) to a financial institution, on a non-recourse basis, in order to be paid earlier than our payment terms require. The Cigna Group is not a party to the program and agrees to commercial terms with its suppliers independently of their participation in the program. Amounts due to suppliers that participate in the program are generally paid within one month following the invoice date. A supplier's participation in the program has no impact on the Company's payment terms and the Company has no economic interest in a supplier's decision to participate in the program. The suppliers, at their sole discretion, determine which invoices, if any, to sell to the financial institution. No guarantees or pledged assets are provided by the Company or any of our subsidiaries under the program. As of March 31, 2023 and December 31, 2022, $1.5 billion and $1.3 billion, respectively, of the Company's outstanding payment obligations were confirmed as valid within the program by the financial institution and reflected in Accounts payable in the Consolidated Balance Sheets. The amounts confirmed as valid for both periods are predominately associated with one supplier. We have been informed by the financial institution that $324 million as of March 31, 2023 of the Company's outstanding payment obligations were voluntarily elected by suppliers to be sold to the financial institution under the program.

Mergers, Acquisitions and Dives

Mergers, Acquisitions and Divestitures	3 Months Ended
Mergers, Acquisitions and Divestitures	Mar. 31, 2023
Business Combination and Asset Acquisition [Abstract]
Mergers, Acquisitions and Divestitures	Note 5 – Mergers, Acquisitions and Divestitures Divestiture of International BusinessesIn July 2022, the Company completed the sale of its life, accident and supplemental benefits businesses in six countries (Hong Kong, Indonesia, New Zealand, South Korea, Taiwan and Thailand) (the "Chubb transaction") for approximately $5.4 billion in cash. The Company recognized a gain of $1.7 billion pre-tax ($1.4 billion after-tax), which includes recognition of previously unrealized capital losses on investments sold and translation loss on foreign currencies. In December 2022, the Company also divested its ownership interest in a joint venture in Türkiye.Integration and Transaction-related CostsIn 2023 and 2022, the Company incurred net costs mainly related to the Chubb transaction. In the first three months of 2022, the Company also incurred net costs related to the sale of the Group Disability and Life business and acquisition of MDLIVE. These net costs were $1 million pre-tax ($1 million after-tax) for the three months ended March 31, 2023 and $52 million pre-tax ($37 million after-tax) for the three months ended March 31, 2022. These costs consisted primarily of certain projects to separate or integrate the Company's systems, products and services, fees for legal, advisory and other professional services and certain employment-related costs.

Earnings Per Share

Earnings Per Share	3 Months Ended
Earnings Per Share	Mar. 31, 2023
Earnings Per Share [Abstract]
Earnings Per Share	Note 6 – Earnings Per ShareBasic and diluted earnings per share were computed as follows: Three Months Ended March 31, 2023 March 31, 2022 (Shares in thousands, dollars in millions, except per share amounts) Basic Effect of Diluted Basic Effect of Diluted Shareholders' net income $ 1,267 $ 1,267 $ 1,197 $ 1,197 Shares: Weighted average 295,706 295,706 318,487 318,487 Common stock equivalents 3,293 3,293 2,795 2,795 Total shares 295,706 3,293 298,999 318,487 2,795 321,282 Earnings per share $ 4.28 $ (0.04) $ 4.24 $ 3.76 $ (0.03) $ 3.73 Amounts reflected above for the three months ended March 31, 2022 have been restated to reflect the impact of adopting amended accounting guidance for long-duration insurance contracts (discussed in Note 2 to the Consolidated Financial Statements). The following outstanding employee stock options were not included in the computation of diluted earnings per share because their effect was anti-dilutive: Three Months Ended March 31, (In millions) 2023 2022 Anti-dilutive options 0.9 2.8

Debt

Debt	3 Months Ended
Debt	Mar. 31, 2023
Debt Disclosure [Abstract]
Debt	Note 7 – Debt The outstanding amounts of debt, net of issuance costs, discounts or premiums, and finance leases were as follows: (In millions) March 31, 2023 December 31, 2022 Short-term debt $17 million, 8.300% Notes due January 2023 — 17 $63 million, 7.650% Notes due March 2023 — 63 $700 million, Floating Rate Notes due July 2023 700 700 $1,000 million, 3.000% Notes due July 2023 996 994 $1,187 million, 3.750% Notes due July 2023 1,187 1,186 $500 million, 0.613% Notes due March 2024 499 — Other, including finance leases 36 33 Total short-term debt $ 3,418 $ 2,993 Long-term debt $500 million, 0.613% Notes due March 2024 — 499 $1,000 million, 3.500% Notes due June 2024 992 990 $900 million, 3.250% Notes due April 2025 (1) 878 872 $2,200 million, 4.125% Notes due November 2025 2,195 2,195 $1,500 million, 4.500% Notes due February 2026 1,503 1,503 $800 million, 1.250% Notes due March 2026 797 797 $700 million, 5.685% Notes due March 2026 697 — $1,500 million, 3.400% Notes due March 2027 1,440 1,436 $259 million, 7.875% Debentures due May 2027 259 259 $600 million, 3.050% Notes due October 2027 597 597 $3,800 million, 4.375% Notes due October 2028 3,785 3,785 $1,500 million, 2.400% Notes due March 2030 1,492 1,492 $1,500 million, 2.375% Notes due March 2031 (1) 1,398 1,380 $45 million, 8.080% Step Down Notes due January 2033 (2) 45 45 $800 million, 5.400% Notes due March 2033 794 — $190 million, 6.150% Notes due November 2036 190 190 $2,200 million, 4.800% Notes due August 2038 2,192 2,192 $750 million, 3.200% Notes due March 2040 743 743 $121 million, 5.875% Notes due March 2041 119 119 $448 million, 6.125% Notes due November 2041 488 488 $317 million, 5.375% Notes due February 2042 315 315 $1,500 million, 4.800% Notes due July 2046 1,466 1,466 $1,000 million, 3.875% Notes due October 2047 989 989 $3,000 million, 4.900% Notes due December 2048 2,969 2,968 $1,250 million, 3.400% Notes due March 2050 1,236 1,236 $1,500 million, 3.400% Notes due March 2051 1,478 1,478 Other, including finance leases 67 66 Total long-term debt $ 29,124 $ 28,100 (1) The Company has entered into interest rate swap contracts hedging a portion of these fixed-rate debt instruments. See Note 11 in the Company's 2022 Form 10-K for further information about the Company's interest rate risk management and these derivative instruments. (2) Interest rate step down to 8.080% effective January 15, 2023. Long-term debt Debt Issuance. On March 7, 2023, the Company issued $1.5 billion of new senior notes. The proceeds of this issuance will be used for general corporate purposes, and may include repayment of outstanding debt securities. Interest on this debt is paid semi-annually. Principal Maturity Date Interest Rate Net Proceeds $700 million (1) March 15, 2026 5.685% $698 million $800 million (2) March 15, 2033 5.400% $796 million (1) Redeemable at any time discounted at the U.S. Treasury rate plus 20 basis points. Redeemable at par on or after March 15, 2024. (2) Redeemable at any time discounted at the U.S. Treasury rate plus 25 basis points. Redeemable at par on or after December 15, 2032. Short-term and Credit Facilities Debt Revolving Credit Agreements. Our revolving credit agreements provide us with the ability to borrow amounts for general corporate purposes, including providing liquidity support if necessary under our commercial paper program discussed below. In April 2023, The Cigna Group entered into the following revolving credit agreements (the "Credit Agreements"), which replaced the agreements discussed above: • a $4.0 billion five-year revolving credit and letter of credit agreement that will mature in April 2028 with an option to extend the maturity date for additional one-year periods, subject to consent of the banks. The Company can borrow up to $4.0 billion under the credit agreement for general corporate purposes, with up to $500 million available for issuance of letters of credit. • a $1.0 billion 364-day revolving credit agreement that will mature in April 2024. The Company can borrow up to $1.0 billion under the credit agreement for general corporate purposes. This agreement includes the option to "term out" any revolving loans that are outstanding at maturity by converting them into a term loan maturing on the one-year anniversary of conversion. Each of the Credit Agreements include an option to increase commitments in an aggregate amount of up to $1.5 billion across both facilities for a maximum total commitment of $6.5 billion. The Credit Agreements allow for borrowings at either a base rate or an adjusted term Secured Overnight Funding Rate ("SOFR") plus, in each case, an applicable margin based on the Company's senior unsecured credit ratings. Each of the two facilities is diversified among 21 large commercial banks, all of which had an A- equivalent or higher rating by at least one Nationally Recognized Statistical Rating Organization as of March 31, 2023. Each facility also contains customary covenants and restrictions, including a financial covenant that the Company's leverage ratio, as defined in the Credit Agreements, may not exceed 60% subject to certain exceptions upon the consummation of an acquisition. Commercial Paper. Under our commercial paper program, we may issue short-term, unsecured commercial paper notes privately placed on a discounted basis through certain broker-dealers at any time not to exceed an aggregate amount of $5.0 billion. Amounts available under the program may be borrowed, repaid and re-borrowed from time to time. The net proceeds of issuances have been and are expected to be used for general corporate purposes. There was no commercial paper outstanding balance as of March 31, 2023. Debt Covenants. The Company was in compliance with its debt covenants as of March 31, 2023. Interest Expense Interest expense on long-term and short-term debt was $345 million for the three months ended March 31, 2023 and $314 million for the three months ended March 31, 2022.

Common and Preferred Stock

Common and Preferred Stock	3 Months Ended
Common and Preferred Stock	Mar. 31, 2023
Equity [Abstract]
Common and Preferred Stock	Note 8 – Common and Preferred Stock Dividends In the first quarter of 2023, The Cigna Group declared quarterly cash dividends of $1.23 per share of the Company's common stock. In the first quarter of 2022, The Cigna Group declared quarterly cash dividends of $1.12 per share of the Company's common stock. The following table provides details of the Company's dividend payments: Record Date Payment Date Amount per Share Total Amount Paid (in millions) 2023 March 8, 2023 March 23, 2023 $1.23 $368 2022 March 9, 2022 March 24, 2022 $1.12 $357 On April 26, 2023, the Board of Directors declared the second quarter cash dividend of $1.23 per share of The Cigna Group common stock to be paid on June 22, 2023 to shareholders of record on June 7, 2023. The Company currently intends to pay regular quarterly

Insurance and Contractholder Li

Insurance and Contractholder Liabilities	3 Months Ended
Insurance and Contractholder Liabilities	Mar. 31, 2023
Insurance Loss Reserves [Abstract]
Insurance and Contractholder Liabilities	Insurance and Contractholder Liabilities A. Account Balances – Insurance and Contractholder Liabilities The Company's insurance and contractholder liabilities were comprised of the following: March 31, 2023 December 31, 2022 March 31, 2022 (In millions) Current Non-current Total Current Non-current Total Total Unpaid claims and claim expenses Cigna Healthcare $ 4,880 $ 79 $ 4,959 $ 4,117 $ 59 $ 4,176 $ 4,491 Other Operations 97 175 272 107 177 284 744 Future policy benefits Cigna Healthcare 59 542 601 43 544 587 681 Other Operations 290 3,341 3,631 150 3,442 3,592 7,981 Contractholder deposit funds Cigna Healthcare 12 151 163 14 157 171 181 Other Operations 361 6,309 6,670 351 6,358 6,709 6,843 Market risk benefits 48 1,172 1,220 51 1,217 1,268 1,558 Unearned premiums 1,419 21 1,440 576 22 598 1,030 Total 23,509 Insurance and contractholder liabilities classified as Liabilities of businesses held for sale (1) (4,562) Total insurance and contractholder liabilities $ 7,166 $ 11,790 $ 18,956 $ 5,409 $ 11,976 $ 17,385 $ 18,947 (1) Amounts classified as Liabilities of businesses held for sale primarily include $3.7 billion of Future policy benefits, $0.4 billion of Unpaid claims and $0.4 billion of Unearned premiums as of March 31, 2022. Insurance and contractholder liabilities expected to be paid within one year are classified as current. The Company adopted amended accounting guidance for long-duration insurance contracts on January 1, 2023, discussed further in Note 2 to the Consolidated Financial Statements, which resulted in restatement of prior period amounts. Additionally, see below updated accounting policies and incremental disclosures associated with future policy benefits (Note 9C), contractholder deposit funds (Note 9D), and market risk benefits (Note 9E). Activity, net of intercompany transactions, in the unpaid claims liability for the Cigna Healthcare segment was as follows: Three Months Ended (In millions) March 31, 2023 March 31, 2022 Beginning balance $ 4,176 $ 4,261 Less: Reinsurance and other amounts recoverable 221 261 Beginning balance, net 3,955 4,000 Incurred costs related to: Current year 9,041 8,024 Prior years (144) (276) Total incurred 8,897 7,748 Paid costs related to: Current year 5,316 4,634 Prior years 2,795 2,822 Total paid 8,111 7,456 Ending balance, net 4,741 4,292 Add: Reinsurance and other amounts recoverable 218 199 Ending balance $ 4,959 $ 4,491 Reinsurance and other amounts recoverable reflect amounts due from reinsurers and policyholders to cover incurred but not reported and pending claims of certain business for which the Company administers the plan benefits without any right of offset. See Note 10 to the Consolidated Financial Statements for additional information on reinsurance. Variances in incurred costs related to prior years' unpaid claims and claim expenses that resulted from the differences between actual experience and the Company's key assumptions were as follows: Three Months Ended March 31, 2023 March 31, 2022 (Dollars in millions) $ % (1) $ % (2) Actual completion factors $ 1 — % $ 99 0.3 % Medical cost trend 143 0.5 177 0.6 Total favorable variance $ 144 0.5 % $ 276 0.9 % (1) Percentage of current year incurred costs as reported for the year ended December 31, 2022. (2) Percentage of current year incurred costs as reported for the year ended December 31, 2021. Favorable prior year development in both years reflects lower than expected utilization of medical services as compared to our assumptions. Accounting Policy. Future policy benefits represent the present value of estimated future obligations, estimated using actuarial methods, for long-term insurance policies and annuity products currently in force, consisting primarily of reserves for annuity contracts, life insurance benefits, and certain supplemental health products that are guaranteed renewable beyond one year. Contracts are grouped at a level no higher than issue year, based on the original contract issue date, and at lower levels of disaggregation within each issue year for certain businesses to reflect factors including product type, plan type and currency. Management estimates these obligations based on assumptions for premiums, interest rates, mortality or morbidity, future claim adjudication expenses and surrenders. Mortality, morbidity and surrender assumptions are based on the Company's own experience and published actuarial tables, and are updated at least annually, to the extent changes in circumstances require. Interest rate assumptions are based on market-level yields for low credit risk fixed income instruments ("upper-medium grade fixed-income instrument"). For interest accretion purposes, interest rates are fixed at the year of the cohort's inception, however for purposes of liability measurement, are updated to the current rate quarterly, with all changes in the interest rate from inception to current period reported through Accumulated other comprehensive loss. For contracts issued domestically, we use observable inputs from a published spot rate curve for terms up to 30 years and extrapolate for longer terms using a constant forward rate approach. For contracts issued by foreign operating entities with functional currencies other than the U.S. dollar, we use observable inputs to approximate a risk free rate and add a credit spread adjustment to align with a low credit risk fixed income instrument. For terms beyond the last observable risk free rates, which vary by international market, we extrapolate to the ultimate forward rate assuming a constant credit spread. For the annuity business, the premium paying period is shorter than the benefit coverage period, and a deferred profit liability ("DPL") is reported in future policy benefits representing gross premium received in excess of net premiums. DPL is amortized based on expected future benefit payments. Cigna Healthcare The weighted average interest rates applied and duration for future policy benefits in the Cigna Healthcare segment, consisting primarily of supplemental health products including individual Medicare supplement, limited benefit health products and individual private medical insurance, were as follows: As of March 31, 2023 March 31, 2022 Interest accretion rate 2.59 % 2.64 % Current discount rate 5.29 % 4.90 % Weighted average duration 8.05 years 7.45 years The net liability for future policy benefits for the segment's supplemental health products represents the present value of benefits expected to be paid to policyholders, net of the present value of expected net premiums, which is the portion of expected future gross premium expected to be collected from policyholders that is required to provide for all expected future benefits and expenses. The present values of expected net premiums and expected future policy benefits for the Cigna Healthcare segment are as follows: Three Months Ended (In millions) March 31, 2023 March 31, 2022 Present value of expected net premiums Beginning balance $ 8,557 $ 9,314 Reversal of effect of beginning of period discount rate assumptions 1,537 (367) Effect of assumption changes and actual variances from expected experience — — Issuances and lapses 306 143 Net premiums collected (326) (310) Interest and other (1) 56 46 Ending balance at original discount rate 10,130 8,826 Effect of end of period discount rate assumptions (1,312) (376) Ending balance (2) $ 8,818 $ 8,450 Present value of expected policy benefits Beginning balance $ 8,945 $ 9,794 Reversal of effect of discount rate assumptions 1,611 (379) Effect of assumption changes and actual variances from expected experience — — Issuances and lapses 307 215 Benefit payments (326) (385) Interest and other (1) 58 52 Ending balance at original discount rate 10,595 9,297 Effect of discount rate assumptions (1,378) (392) Ending balance (3) $ 9,217 $ 8,905 Liability for future policy benefits $ 399 $ 455 Other (4) 202 226 Total liability for future policy benefits (5) $ 601 $ 681 (1) Includes the foreign exchange rate impact of translating from transactional and functional currency to United States dollar and the impact of flooring the liability at zero. The flooring impact is calculated at the cohort level after discounting the reserves at the current discount rate. (2) As of March 31, 2023 and March 31, 2022, respectively, undiscounted expected future gross premiums were $17.6 billion and $13.5 billion. As of March 31, 2023 and March 31, 2022, respectively, discounted expected future gross premiums were $12.5 billion and $10.7 billion. (3) As of March 31, 2023 and March 31, 2022, respectively, undiscounted expected future policy benefits were $12.8 billion and $11.2 billion. (4) The liability for future policyholder benefits includes immaterial businesses shown as reconciling items above, most of which are in run-off. (5) $154 million and $171 million of reinsurance recoverable asset reported in the Consolidated Balance Sheets as of March 31, 2023 and March 31, 2022, respectively, relate to the liability for future policy benefits. Other Operations The weighted average interest rates applied and duration for future policy benefits in Other Operations, consisting of annuity and life insurance products, were as follows: As of March 31, 2023 March 31, 2022 Interest accretion rate 5.64 % 5.64 % Current discount rate 4.95 % 3.59 % Weighted average duration 11.7 years 13.9 years Obligations for annuities represent discounted periodic benefits to be paid to an individual or groups of individuals over their remaining lives. Other Operations ' traditional insurance contracts, which are in run-off, have no premium remaining to be collected; therefore, future policy benefit reserves represent the present value of expected future policy benefits, discounted using the current discount rate and the remaining amortizable DPL. Future policy benefits for Other Operations includes DPL of $392 million as of March 31, 2023 and $384 million as of March 31, 2022. Future policy benefits excluding DPL, were $3.2 billion as of both March 31, 2023 and December 31, 2022 and $3.9 billion and $4.3 billion as of March 31, 2022 and December 31, 2021, respectively. These balances exclude amounts classified as Liabilities of businesses held for sale of $3.7 billion as of March 31, 2022 and $3.8 billion as of December 31, 2021. The change in future policy benefits reserves year-to-date was primarily driven by changes in the current discount rate. Undiscounted expected future policy benefits were $4.6 billion as of March 31, 2023 and $4.7 billion as of March 31, 2022. As of March 31, 2023 and March 31, 2022, $1.0 billion and $1.2 billion of the future policy benefit reserve was recoverable through treaties with external reinsurers. Accounting Policy. Liabilities for contractholder deposit funds primarily include deposits received from customers for investment-related and universal life products and investment earnings on their fund balances in Other Operations. These liabilities are adjusted to reflect administrative charges and, for universal life fund balances, mortality charges. Interest credited on these funds is accrued ratably over the contract period. Accounting Policy. Variable annuity reinsurance liabilities are measured as MRBs at fair value, net of nonperformance risk, with fluctuations in value gross of reinsurer nonperformance risk reported in benefits expense while fluctuations in the Company's own Market risk benefits activity was as follows: Three Months Ended (Dollars in millions) March 31, 2023 March 31, 2022 Balance, beginning of year $ 1,268 $ 1,824 Balance, beginning of year, before the effect of nonperformance risk (own credit risk) 1,379 1,949 Changes due to expected run-off (6) (19) Changes due to capital markets versus expected (41) (271) Changes due to policyholder behavior versus expected 6 (9) Assumption changes (33) 39 Balance, end of year, before the effect of changes in nonperformance risk (own credit risk) 1,305 1,689 Nonperformance risk (own credit risk), end of period (85) (131) Balance, end of period $ 1,220 $ 1,558 Reinsured market risk benefit, end of period $ 1,301 $ 1,681 The following table presents the net amount at risk and the average attained age of contractholders (weighted by exposure) for contracts assumed by the Company. The net amount at risk is the amount the Company would have to pay to contractholders if all deaths or annuitizations occurred as of the earliest possible date in accordance with the insurance contract. The Company should be reimbursed in full for these payments unless the Berkshire reinsurance limit is exceeded, as discussed further in Note 10 to the Consolidated Financial Statements. (Dollars in millions, excludes impact of reinsurance ceded) March 31, 2023 March 31, 2022 Net amount at risk $ 2,183 $ 1,892 Average attained age of contractholders (weighted by exposure) 75.4 years 76.4 years

Reinsurance

Reinsurance	3 Months Ended
Reinsurance	Mar. 31, 2023
Reinsurance Disclosures [Abstract]
Reinsurance	Note 10 – Reinsurance The Company's insurance subsidiaries enter into agreements with other insurance companies to limit losses from large exposures and to permit recovery of a portion of incurred losses. Reinsurance is ceded primarily in acquisition and disposition transactions when the underwriting company is not being acquired. Reinsurance does not relieve the originating insurer of liability. Therefore, reinsured liabilities must continue to be reported along with the related reinsurance recoverables. The Company regularly evaluates the financial condition of its reinsurers and monitors concentrations of its credit risk. The majority of the Company's reinsurance recoverables resulted from acquisition and disposition transactions in which the underwriting company was not acquired. The Company bears the risk of loss if its reinsurers and retrocessionaires do not meet or are unable to meet their reinsurance obligations to the Company. The Company reviews its reinsurance arrangements and establishes reserves against the recoverables. The Company's reinsurance recoverables as of March 31, 2023 are presented at amount due by range of external credit rating and collateral level in the following table, with reinsurance recoverables that are market risk benefits separately presented at fair value: (In millions) Fair value of collateral contractually required to meet or exceed carrying value of recoverable Collateral provisions exist that may mitigate risk of credit loss (3) No collateral Total Ongoing Operations A- equivalent and higher current ratings (1) $ — $ — $ 94 $ 94 BBB- to BBB+ equivalent current credit ratings (1) — — 59 59 Not rated 142 5 63 210 Total recoverables related to ongoing operations (2) 142 5 216 363 Acquisition, disposition or run-off activities BBB+ equivalent and higher current ratings (1) Lincoln National Life and Lincoln Life & Annuity of New York — 2,750 — 2,750 Empower Annuity Insurance Company — — 133 133 Prudential Insurance Company of America 380 — — 380 Life Insurance Company of North America — 386 — 386 Other 187 25 15 227 Not rated — 9 3 12 Total recoverables related to acquisition, disposition or run-off activities 567 3,170 151 3,888 Total reinsurance recoverables before market risk benefits $ 709 $ 3,175 $ 367 $ 4,251 Allowance for uncollectible reinsurance (35) Market risk benefits (4) 1,301 Total reinsurance recoverables (2) $ 5,517 (1) Certified by a Nationally Recognized Statistical Rating Organization ("NRSRO"). (2) Includes $231 million of current reinsurance recoverables that are reported in Other current assets. (3) Includes collateral provisions requiring the reinsurer to fully collateralize its obligation if its external credit rating is downgraded to a specified level. (4) Total Berkshire and certain Other recoverables reflected under acquisition, disposition or run-off activities in the Company's 2022 Form 10-K that relate to the Company’s variable annuity reinsurance products discussed in section B below are now reported at fair market value as MRBs, as further discussed in Note 9 to the Consolidated Financial Statements. At December 31, 2022, we reported $711 million related to these recoverables related to the GMDB variable annuity reinsurance product. The restated December 31, 2022 variable annuity reinsurance recoverable balance is $1.4 billion, which also includes the GMIB variable annuity reinsurance product that was classified in Other assets prior to the adoption of LDTI. Collateral levels are defined internally based on the fair value of the collateral relative to the carrying amount of the reinsurance recoverable, the frequency at which collateral is required to be replenished and the potential for volatility in the collateral's fair value. (In millions) Reinsurer (1) March 31, 2023 December 31, 2022 Collateral and Other Terms at March 31, 2023 Berkshire $ 1,043 $ 1,116 90% were secured by assets in a trust. Sun Life Assurance Company of Canada 117 115 Liberty Re (Bermuda) Ltd. 128 128 100% were secured by assets in a trust. SCOR SE 35 39 70% were secured by a letter of credit. Market risk benefits (2) $ 1,323 $ 1,398 (1) All reinsurers are rated A- equivalent and higher by an NRSRO. (2) Includes IBNR and outstanding claims of $25 million offset by premium due of $3 million. These amounts are excluded from market risk benefits at March 31, 2023 in Note 9 and Note 10A to the Consolidated Financial Statements. At December 31, 2022, IBNR and outstanding claims of $27 million offset by premium due of $3 million were excluded from the market risk benefits as restated due to the adoption of LDTI. The impact of nonperformance risk (i.e. the risk that a counterparty might default) on the variable annuity reinsurance asset was immaterial for the three months ended March 31, 2023 and March 31, 2022.

Investments

Investments	3 Months Ended
Investments	Mar. 31, 2023
Investments [Abstract]
Investments	Note 11 – InvestmentsThe Cigna Group's investment portfolio consists of a broad range of investments including debt securities, equity securities, commercial mortgage loans, policy loans, other long-term investments, short-term investments and derivative financial instruments. The sections below provide more detail regarding our investment balances and realized investment gains and losses. See Note 12 to the Consolidated Financial Statements for information about the valuation of the Company's investment portfolio. Further information about our accounting policies for investment assets can be found in Note 11 in the Company's 2022 Form 10-K. The following table summarizes the Company's investments by category and current or long-term classification: March 31, 2023 December 31, 2022 (In millions) Current Long-term Total Current Long-term Total Debt securities $ 616 $ 9,293 $ 9,909 $ 654 $ 9,218 $ 9,872 Equity securities 51 3,069 3,120 45 577 622 Commercial mortgage loans 106 1,501 1,607 67 1,547 1,614 Policy loans — 1,211 1,211 — 1,218 1,218 Other long-term investments — 3,936 3,936 — 3,728 3,728 Short-term investments 141 — 141 139 — 139 Total $ 914 $ 19,010 $ 19,924 $ 905 $ 16,288 $ 17,193 Accounting policy. Our accounting policy for debt securities (including bonds, mortgage and other asset-backed securities and preferred stocks redeemable by the investor) remains materially consistent with the policy disclosed in the Company's 2022 Form 10-K. However, with the adoption of amended accounting guidance for long-duration insurance contracts on January 1, 2023 (discussed in Note 2 to the Consolidated Financial Statements), net unrealized appreciation on debt securities supporting the Company's run-off settlement annuity business is no longer reported in Non-current insurance and contractholder liabilities but rather is reported in Accumulated other comprehensive loss. See Note 14 to the Consolidated Financial Statements for the impact to Accumulated other comprehensive loss. The amortized cost and fair value by contractual maturity periods for debt securities were as follows as of March 31, 2023: (In millions) Amortized Fair Due in one year or less $ 638 $ 630 Due after one year through five years 3,972 3,752 Due after five years through ten years 3,227 2,915 Due after ten years 2,450 2,268 Mortgage and other asset-backed securities 381 344 Total $ 10,668 $ 9,909 Actual maturities of these securities could differ from their contractual maturities used in the table above because issuers may have the right to call or prepay obligations, with or without penalties. Gross unrealized appreciation (depreciation) on debt securities by type of issuer is shown below: (In millions) Amortized Allowance for Credit Loss Unrealized Unrealized Fair March 31, 2023 Federal government and agency $ 276 $ — $ 29 $ (8) $ 297 State and local government 42 — — (1) 41 Foreign government 373 — 16 (18) 371 Corporate 9,596 (41) 124 (823) 8,856 Mortgage and other asset-backed 381 — 1 (38) 344 Total $ 10,668 $ (41) $ 170 $ (888) $ 9,909 December 31, 2022 Federal government and agency $ 292 $ — $ 32 $ (12) $ 312 State and local government 43 — — (2) 41 Foreign government 375 — 11 (21) 365 Corporate 9,742 (44) 89 (981) 8,806 Mortgage and other asset-backed 390 — 1 (43) 348 Total $ 10,842 $ (44) $ 133 $ (1,059) $ 9,872 Review of declines in fair value. Management reviews impaired debt securities to determine whether a credit loss allowance is needed based on criteria that include: • severity of decline; • financial health and specific prospects of the issuer; and • changes in the regulatory, economic or general market environment of the issuer's industry or geographic region. The table below summarizes debt securities with a decline in fair value from amortized cost for which an allowance for credit losses has not been recorded, by investment grade and the length of time these securities have been in an unrealized loss position. Unrealized depreciation on these debt securities is primarily due to declines in fair value resulting from increasing interest rates since these securities were purchased. March 31, 2023 December 31, 2022 (Dollars in millions) Fair Amortized Unrealized Number Fair Amortized Unrealized Number One year or less Investment grade $ 3,176 $ 3,362 $ (186) 1,019 $ 5,533 $ 6,127 $ (594) 1,659 Below investment grade 353 371 (18) 936 887 964 (77) 1,287 More than one year Investment grade 3,222 3,808 (586) 1,035 1,151 1,487 (336) 462 Below investment grade 682 780 (98) 770 330 382 (52) 369 Total $ 7,433 $ 8,321 $ (888) 3,760 $ 7,901 $ 8,960 $ (1,059) 3,777 Equity Securities The following table provides the values of the Company's equity security investments as of March 31, 2023 and December 31, 2022: March 31, 2023 December 31, 2022 (In millions) Cost Carrying Value Cost Carrying Value Equity securities with readily determinable fair values $ 680 $ 91 $ 673 $ 138 Equity securities with no readily determinable fair value 2,926 3,029 380 484 Total $ 3,606 $ 3,120 $ 1,053 $ 622 Consistent with our strategy to invest in targeted startup and growth-stage companies in the health care industry, approximately 95% of our investments in equity securities are in the health care sector. The following table summarizes the credit risk profile of the Company's commercial mortgage loan portfolio: (Dollars in millions) March 31, 2023 December 31, 2022 Loan-to-Value Ratio Carrying Value Average Debt Service Coverage Ratio Average Loan-to-Value Ratio Carrying Value Average Debt Service Coverage Ratio Average Loan-to-Value Ratio Below 60% $ 912 2.11 $ 901 2.12 60% to 79% 504 1.73 564 1.73 80% to 100% 191 1.32 149 1.17 Total $ 1,607 1.89 60 % $ 1,614 1.89 60 % Other Long-Term Investments Other long-term investments include investments in unconsolidated entities, including certain limited partnerships and limited liability companies holding real estate, securities or loans. These investments are carried at cost plus the Company's ownership percentage of reporting income or loss, based on the financial statements of the underlying investments that are generally reported at fair value. Income or loss from these investments is reported on a one quarter lag due to the timing of when financial information is received from the general partner or manager of the investments. Other long-term investments also include investment real estate carried at depreciated cost less any impairment write-downs to fair value when cash flows indicate that the carrying value may not be recoverable. Additionally, statutory and other restricted deposits and foreign currency swaps carried at fair value are reported in the table below as Other. The following table provides the carrying value information for these investments: Carrying Value as of (In millions) March 31, 2023 December 31, 2022 Real estate investments $ 1,434 $ 1,319 Securities partnerships 2,259 2,166 Other 243 243 Total $ 3,936 $ 3,728 Accounting policy. Realized investment gains and losses are based on specifically identified assets and result from sales, investment asset write-downs, change in the fair value of certain derivatives and equity securities and changes in allowances for credit losses on debt securities and commercial mortgage loan investments. With the adoption of amended accounting guidance for long-duration insurance contracts on January 1, 2023 (discussed in Note 2 to the Consolidated Financial Statements), realized investment gains and losses no longer exclude amounts that were previously required to adjust future policy benefits for the run-off settlement annuity business. Prior period net realized investment losses have been updated to reflect the impact of adopting LDTI. The following realized gains and losses on investments exclude realized gains and losses attributed to the Company's separate accounts because those gains and losses generally accrue directly to separate account policyholders: Three Months Ended March 31, (In millions) 2023 2022 Net realized investment (losses), excluding credit loss expense and asset write-downs $ (51) $ (322) Credit loss recoveries 3 — Other investment asset write-downs (8) — Net realized investment (losses), before income taxes $ (56) $ (322)

Fair Value Measurements

Fair Value Measurements	3 Months Ended
Fair Value Measurements	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 12 – Fair Value Measurements The Company carries certain financial instruments at fair value in the financial statements including debt securities, certain equity securities, short-term investments and derivatives. Other financial instruments are measured at fair value only under certain conditions, such as when impaired or when there are observable price changes for equity securities with no readily determinable fair value. Fair value is defined as the price at which an asset could be exchanged in an orderly transaction between market participants at the balance sheet date. A liability's fair value is defined as the amount that would be paid to transfer the liability to a market participant, not the amount that would be paid to settle the liability with the creditor. The Company's financial assets and liabilities carried at fair value have been classified based upon a hierarchy defined by GAAP. The hierarchy gives the highest ranking to fair values determined using unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest ranking to fair values determined using methodologies and models with unobservable inputs (Level 3). An asset's or a liability's classification is based on the lowest level of input that is significant to its measurement. For example, a financial asset or liability carried at fair value would be classified in Level 3 if unobservable inputs were significant to the instrument's fair value, even though the measurement may be derived using inputs that are both observable (Levels 1 and 2) and unobservable (Level 3). The following table provides information about the Company's financial assets and liabilities carried at fair value. Further information regarding insurance assets and liabilities carried at fair value is provided in Note 9E to the Consolidated Financial Statements. Separate account assets are also recorded at fair value on the Company's Consolidated Balance Sheets and are reported separately in the Separate Accounts section below as gains and losses related to these assets generally accrue directly to contractholders: (In millions) Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total March 31, 2023 December 31, 2022 March 31, 2023 December 31, 2022 March 31, 2023 December 31, 2022 March 31, 2023 December 31, 2022 Financial assets at fair value Debt securities Federal government and agency $ 151 $ 147 $ 146 $ 165 $ — $ — $ 297 $ 312 State and local government — — 41 41 — — 41 41 Foreign government — — 371 365 — — 371 365 Corporate — — 8,421 8,394 435 412 8,856 8,806 Mortgage and other asset-backed — — 309 313 35 35 344 348 Total debt securities 151 147 9,288 9,278 470 447 9,909 9,872 Equity securities (1) 6 6 84 132 1 — 91 138 Short-term investments — — 141 139 — — 141 139 Derivative assets — — 206 230 1 1 207 231 (1) Excludes certain equity securities that have no readily determinable fair value. Level 3 Financial Assets and Financial Liabilities Certain inputs for instruments classified in Level 3 are unobservable (supported by little or no market activity) and significant to their resulting fair value measurement. Unobservable inputs reflect the Company's best estimate of what hypothetical market participants would use to determine a transaction price for the asset or liability at the reporting date. Additionally, as discussed in Note 9 to the Consolidated Financial Statements, the Company classifies variable annuity assets and liabilities in Level 3 of the fair value hierarchy. Quantitative Information about Unobservable Inputs The significant unobservable input used to value our corporate and government debt securities and mortgage and other asset-backed securities is an adjustment for liquidity. This adjustment is needed to reflect current market conditions and issuer circumstances when there is limited trading activity for the security. The following table summarizes the fair value and significant unobservable inputs that were developed directly by the Company and used in pricing these debt securities. The range and weighted average basis point ("bps") amounts for liquidity reflect the Company's best estimates of the unobservable adjustments a market participant would make to calculate these fair values. Fair Value as of Unobservable Adjustment Range (Weighted Average by Quantity) as of (Fair value in millions) March 31, 2023 December 31, 2022 Unobservable input March 31, 2023 March 31, 2023 December 31, 2022 Debt securities Corporate and government debt securities $ 433 $ 412 Liquidity 60 - 1060 (300) bps 60 - 1060 (270) bps Mortgage and other asset-backed securities 35 35 Liquidity 105 - 520 (310) bps 110 - 520 (310) bps Other debt securities 2 — Total Level 3 debt securities $ 470 $ 447 A significant increase in liquidity spread adjustments would result in a lower fair value measurement, while a decrease would result in a higher fair value measurement. Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value The following table summarizes the changes in financial assets and financial liabilities classified in Level 3. Gains and losses reported in the table may include net changes in fair value that are attributable to both observable and unobservable inputs. For the Three Months Ended (In millions) 2023 2022 Debt and Equity Securities Beginning balance $ 447 $ 796 Gains included in Shareholders' net income 1 12 Gains (losses) included in Other comprehensive loss 5 (15) Losses required to adjust future policy benefits for settlement annuities (1) — (12) Purchases, sales and settlements Purchases 4 49 Settlements (9) (81) Total purchases, sales and settlements (5) (32) Transfers into/(out of) Level 3 Transfers into Level 3 39 101 Transfers out of Level 3 (16) (164) Total transfers into/(out of) Level 3 23 (63) Ending balance $ 471 $ 686 Total gains included in Shareholders' net income attributable to instruments held at the reporting date $ 1 $ — Change in unrealized gain or (loss) included in Other comprehensive loss for assets held at the end of the reporting period $ 5 $ (13) (1) Amounts do not accrue to shareholders. Total gains and losses included in Shareholders' net income in the tables above are reflected in the Consolidated Statements of Income as Net realized investment losses and Net investment income. Gains and losses included in Other comprehensive loss, net of tax in the tables above are reflected in Net unrealized appreciation (depreciation) on securities and derivatives in the Consolidated Statements of Comprehensive Income. Transfers into or out of the Level 3 category occur when unobservable inputs, such as the Company's best estimate of what a market participant would use to determine a current transaction price, become more or less significant to the fair value measurement. Market activity typically decreases during periods of economic uncertainty and this decrease in activity reduces the availability of market observable data. As a result, the level of unobservable judgment that must be applied to the pricing of certain instruments increases and is typically observed through the widening of liquidity spreads. Transfers between Level 2 and Level 3 during 2023 and 2022 primarily reflected changes in liquidity estimates for certain private placement issuers across several sectors. See discussion under Quantitative Information about Unobservable Inputs above for more information. Separate Accounts The investment income and fair value gains and losses of Separate account assets generally accrue directly to the contractholders and, together with their deposits and withdrawals, are excluded from the Company's Consolidated Statements of Income and Cash Flows. Fair values of Separate account assets were as follows: Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total (In millions) March 31, 2023 December 31, 2022 March 31, 2023 December 31, 2022 March 31, 2023 December 31, 2022 March 31, 2023 December 31, 2022 Guaranteed separate accounts (See Note 16) $ 213 $ 203 $ 349 $ 382 $ — $ — $ 562 $ 585 Non-guaranteed separate accounts (1) 221 211 5,586 5,522 213 203 6,020 5,936 Subtotal $ 434 $ 414 $ 5,935 $ 5,904 $ 213 $ 203 6,582 6,521 Non-guaranteed separate accounts priced at net asset value ("NAV") as a practical expedient (1) 758 757 Total $ 7,340 $ 7,278 (1) Non-guaranteed separate accounts include $4.0 billion as of March 31, 2023 and December 31, 2022 in assets supporting the Company's pension plans, including $0.2 billion classified in Level 3 as of March 31, 2023 and December 31, 2022. Separate account assets classified in Level 3 primarily support the Company's pension plans and include certain newly-issued, privately-placed, complex or illiquid securities that are priced using methods discussed above, as well as commercial mortgage loans. Activity, including transfers into and out of Level 3, was not material for the three months ended March 31, 2023 or 2022. Separate account investments in securities partnerships, real estate and hedge funds are generally valued based on the separate account's ownership share of the equity of the investee (NAV as a practical expedient), including changes in the fair values of its underlying investments. Substantially all of these assets support the Company's pension plans. The following table provides additional information on these investments: Fair Value as of Unfunded Commitment as of March 31, 2023 Redemption Frequency Redemption Notice (In millions) March 31, 2023 December 31, 2022 Securities partnerships $ 467 $ 451 $ 228 Not applicable Not applicable Real estate funds 287 302 — Quarterly 30 - 90 days Hedge funds 4 4 — Up to annually, varying by fund 30 - 90 days Total $ 758 $ 757 $ 228 As of March 31, 2023, the Company does not have plans to sell any of these assets at less than fair value. These investments are structured to satisfy longer-term investment objectives. Securities partnerships are contractually non-redeemable and the underlying investment assets are expected to be liquidated by the fund managers within ten years after inception. Some financial assets and liabilities are not carried at fair value, such as commercial mortgage loans that are carried at unpaid principal, investment real estate that is carried at depreciated cost and equity securities with no readily determinable fair value when there are no observable market transactions. However, these financial assets and liabilities may be measured using fair value under certain conditions, such as when investments become impaired and are written down to their fair value, or when there are observable price changes from orderly market transactions of equity securities that otherwise had no readily determinable fair value. For the three months ended March 31, 2023 and 2022, impairments recognized requiring these assets to be measured at fair value were not material. Realized investment gains and losses from these observable price changes for the three months ended March 31, 2023 and March 31, 2022 were not material. The following table includes the Company's financial instruments not recorded at fair value but for which fair value disclosure is required. In addition to universal life products and finance leases, financial instruments that are carried in the Company's Consolidated Balance Sheets at amounts that approximate fair value are excluded from the following table: Classification in Fair Value Hierarchy March 31, 2023 December 31, 2022 (In millions) Fair Value Carrying Value Fair Value Carrying Value Commercial mortgage loans Level 3 $ 1,509 $ 1,607 $ 1,491 $ 1,614 Long-term debt, including current maturities, excluding finance leases Level 2 $ 30,679 $ 32,439 $ 28,653 $ 30,994

Variable Interest Entities

Variable Interest Entities	3 Months Ended
Variable Interest Entities	Mar. 31, 2023
Variable Interest Entities [Abstract]
Variable Interest Entities	Note 13 – Variable Interest EntitiesWe perform ongoing qualitative analyses of our involvement with variable interest entities to determine if consolidation is required. The Company determined that it was not a primary beneficiary in any material variable interest entity as of March 31, 2023 or December 31, 2022. The Company's involvement with variable interest entities for which it is not the primary beneficiary has not changed materially from December 31, 2022. For details of our accounting policy for variable interest entities and the composition of variable interest entities with which the Company is involved, refer to Note 13 in the Company's 2022 Form 10-K. The Company has not provided, and does not intend to provide, financial support to any of these variable interest entities in excess of its maximum exposure.

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income (Loss)	3 Months Ended
Accumulated Other Comprehensive Income (Loss)	Mar. 31, 2023
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Accumulated Other Comprehensive Income (Loss)	Note 14 – Accumulated Other Comprehensive Income (Loss) ("AOCI") AOCI includes net unrealized (depreciation) appreciation on securities and derivatives, change in discount rate and instrument specific credit risk for certain long-duration insurance contractholder liabilities (Note 9 to the Consolidated Financial Statements), foreign currency translation and the net postretirement benefits liability adjustment. AOCI includes the Company's share from unconsolidated entities reported on the equity method. Generally, tax effects in AOCI are established at the currently enacted tax rate and reclassified to Shareholders' net income in the same period that the related pre-tax AOCI reclassifications are recognized. Changes in the components of AOCI, including the impact of adopting amended accounting guidance for long-duration insurance contracts (discussed in Note 2 to the Consolidated Financial Statements), were as follows: Three Months Ended March 31, (In millions) 2023 2022 Securities and Derivatives Beginning balance, as retrospectively restated $ (332) 1,266 Unrealized appreciation (depreciation) on securities and derivatives 252 (1,065) Tax (expense) benefit (54) 231 Net unrealized appreciation (depreciation) on securities and derivatives 198 (834) Reclassification adjustment for (gains) included in Shareholders' net income (Net realized investment losses) (5) (11) Reclassification adjustment for tax expense included in Shareholders' net income 1 2 Net (gains) reclassified from AOCI to Shareholders' net income (4) (9) Other comprehensive income (loss), net of tax 194 (843) Ending balance $ (138) $ 423 Net long-duration insurance and contractholder liabilities measurement adjustments (1) Beginning balance (256) (765) Current period change in discount rate for certain long duration liabilities (411) 584 Tax benefit (expense) 101 (130) Net current period change in discount rate for certain long duration liabilities (310) 454 Current period change in instrument-specific credit risk for market risk benefits (26) 6 Tax benefit (expense) 5 (1) Net current period change in instrument-specific credit risk for market risk benefits (21) 5 Other comprehensive (loss) income, net of tax (331) 459 Ending balance (587) (306) Translation of foreign currencies Beginning balance, as retrospectively restated $ (154) (233) Translation of foreign currencies 15 (60) Tax benefit (expense) 1 (3) Net translation of foreign currencies 16 (63) Less: Net translation (loss) on foreign currencies attributable to noncontrolling interests — (2) Shareholders' other comprehensive income (loss), net of tax 16 (61) Ending balance $ (138) $ (294) Postretirement benefits liability Beginning balance $ (916) $ (1,336) Reclassification adjustment for amortization of net prior actuarial losses and prior service costs (Interest expense and other) 13 16 Reclassification adjustment for tax (benefit) included in Shareholders' net income (3) (3) Net adjustments reclassified from AOCI to Shareholders' net income 10 13 Other comprehensive income, net of tax 10 13 Ending balance $ (906) $ (1,323) Total Accumulated other comprehensive loss Beginning balance, as retrospectively restated (1,658) (1,068) Shareholders' other comprehensive (loss), net of tax (111) (432) Ending balance $ (1,769) $ (1,500) (1) Established upon the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.

Income Taxes

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	Note 15 – Income Taxes Income Tax Expense The 18.4% effective tax rate for the three months ended March 31, 2023 was lower than the 22.7% rate for the three months ended March 31, 2022. This decrease was driven largely by favorable results relative to the Company's foreign operations, partially offset by an increase pertaining to the year over year impact of remeasurement of deferred taxes.

Contingencies and Other Matters

Contingencies and Other Matters	3 Months Ended
Contingencies and Other Matters	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Contingencies and Other Matters	Note 16 – Contingencies and Other Matters The Company, through its subsidiaries, is contingently liable for various guarantees provided in the ordinary course of business. A. Financial Guarantees: Retiree and Life Insurance Benefits The Company guarantees that separate account assets will be sufficient to pay certain life insurance or retiree benefits. For the majority of these benefits, the sponsoring employers are primarily responsible for ensuring that assets are sufficient to pay these benefits and are required to maintain assets that exceed a certain percentage of benefit obligations. If employers fail to do so, the Company or an affiliate of the buyer of the retirement benefits business has the right to redirect the management of the related assets to provide for benefit payments. As of March 31, 2023, employers maintained assets that generally exceeded the benefit obligations under these arrangements of approximately $420 million. An additional liability is established if management believes that the Company will be required to make payments under the guarantees; there were no additional liabilities required for these guarantees, net of reinsurance, as of March 31, 2023. Separate account assets supporting these guarantees are classified in Levels 1 and 2 of the GAAP fair value hierarchy. The Company does not expect that these financial guarantees will have a material effect on the Company's consolidated results of operations, liquidity or financial condition. B. Certain Other Guarantees The Company had indemnification obligations as of March 31, 2023 in connection with acquisition and disposition transactions. These indemnification obligations are triggered by the breach of representations or covenants provided by the Company, such as representations for the presentation of financial statements, filing of tax returns, compliance with law or identification of outstanding litigation. These obligations are typically subject to various time limitations, defined by the contract or by operation of law, such as statutes of limitation. In some cases, the maximum potential amount due is subject to contractual limitations based on a percentage of the transaction purchase price, while in other cases limitations are not specified or applicable. The Company does not believe that it is possible to determine the maximum potential amount due under these obligations because not all amounts due under these indemnification obligations are subject to limitation. There were no liabilities for these indemnification obligations as of March 31, 2023. C. Guaranty Fund Assessments The Company operates in a regulatory environment that may require its participation in assessments under state insurance guaranty association laws. The Company's exposure to assessments for certain obligations of insolvent insurance companies to policyholders and claimants is based on its share of business written in the relevant jurisdictions. There were no material charges or credits resulting from existing or new guaranty fund assessments for the three months ended March 31, 2023. The Company is routinely involved in numerous claims, lawsuits, regulatory inquiries and audits, government investigations, including under the federal False Claims Act and state false claims acts initiated by a government investigating body or by a qui tam relator's filing of a complaint under court seal, and other legal matters arising, for the most part, in the ordinary course of managing a global health services business. Additionally, the Company has received and is cooperating with subpoenas or similar processes from various governmental agencies requesting information, all arising in the normal course of its business. Disputed tax matters arising Litigation Matters Express Scripts Litigation with Elevance . In March 2016, Elevance filed a lawsuit in the United States District Court for the Southern District of New York alleging various breach of contract claims against Express Scripts relating to the parties' rights and obligations under the periodic pricing review section of the pharmacy benefit management agreement between the parties including allegations that Express Scripts failed to negotiate new pricing concessions in good faith, as well as various alleged service issues. Elevance also requested that the court enter declaratory judgment that Express Scripts is required to provide Elevance competitive benchmark pricing, that Elevance can terminate the agreement and that Express Scripts is required to provide Elevance with post-termination services at competitive benchmark pricing for one year following any termination by Elevance. Elevance claimed it is entitled to $13 billion in additional pricing concessions over the remaining term of the agreement, as well as $1.8 billion for one year following any contract termination by Elevance and $150 million damages for service issues ("Elevance's Allegations"). On April 19, 2016, in response to Elevance's complaint, Express Scripts filed its answer denying Elevance's Allegations in their entirety and asserting affirmative defenses and counterclaims against Elevance. The court subsequently granted Elevance's motion to dismiss two of six counts of Express Scripts' amended counterclaims. Express Scripts filed its Motion for Summary Judgment on August 27, 2021. Elevance completed filing of its Response to Express Scripts' Motion for Summary Judgment on October 16, 2021. Express Scripts filed its Reply in Support of its Motion for Summary Judgment on November 19, 2021. On March 31, 2022, the court granted summary judgment in favor of Express Scripts on all of Elevance's pricing claims for damages totaling $14.8 billion and on most of Elevance's claims relating to service issues. Elevance's only remaining service claims relate to the review or processing of prior authorizations. On June 10, 2022, Express Scripts filed a Motion for Partial Summary Judgment seeking to limit Elevance's remaining prior authorization claims and a Motion to Exclude certain opinions offered by its experts. Elevance filed its opposition to both motions, and a cross-motion to submit a supplemental expert report, on July 9, 2022. Express Scripts' pending Motions were fully briefed at the end of July 2022. On March 8, 2023, the Court granted Express Scripts' Motion for Partial Summary Judgement, excluding in full the testimony of four of Elevance's experts and in part the testimony of two additional experts, and granted Elevance leave to submit a supplemental expert report. On April 5, 2023, the Court entered a scheduling order setting a trial on Elevance's remaining prior authorization claims to commence on December 4, 2023. Medicare Advantage. A qui tam action that was filed by a private individual on behalf of the government in the United States District Court for the Southern District of New York in 2017 was unsealed on August 6, 2020. The action asserts claims related to risk adjustment practices arising from certain health exams conducted as part of the Company's Medicare Advantage business. In September 2021, the qui tam action was transferred to the United States District Court for the Middle District of Tennessee. On January 11, 2022, the U.S. Department of Justice ("DOJ") (U.S. Attorney's Offices for the Southern District of New York and the Middle District of Tennessee) filed a motion to partially intervene, which was granted on August 2, 2022. On October 14, 2022, the DOJ filed its complaint-in-intervention alleging that certain diagnoses made during in-home exams were invalid for risk adjustment purposes, seeking unspecified damages and penalties under the federal False Claims Act. The Company filed motions to dismiss the DOJ's complaint and the remainder of the qui tam complaint on December 16, 2022. Briefing is complete and the matter is pending before the court. Regulatory Matters Civil Investigative Demand . The DOJ is conducting industry-wide investigations of Medicare Advantage organizations' risk adjustment practices. For certain Medicare Advantage organizations, including The Cigna Group, those investigations have resulted in litigation (see "Litigation Matters—Medicare Advantage" above). The Company has responded to information requests (civil investigative demands) from the DOJ (U.S. Attorney's Office for the Eastern District of Pennsylvania) and is continuing to cooperate with the DOJ.

Segment Information

Segment Information	3 Months Ended
Segment Information	Mar. 31, 2023
Segment Reporting [Abstract]
Segment Information	Note 17 – Segment Information See Note 1 to the Consolidated Financial Statements for a description of our segments. A description of our basis for reporting segment operating results is outlined below. Intersegment revenues primarily reflect pharmacy and care services transactions between the Evernorth Health Services and Cigna Healthcare segments. The Company uses "pre-tax adjusted income (loss) from operations" and "adjusted revenues" as its principal financial measures of segment operating performance because management believes these metrics best reflect the underlying results of business operations and permit analysis of trends in underlying revenue, expenses and profitability. We define pre-tax adjusted income from operations as income before income taxes excluding pre-tax income (loss) attributable to noncontrolling interests, net realized investment results, amortization of acquired intangible assets, and special items. The Cigna Group's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and The Cigna Group's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or future underlying performance of the business. The Company does not report total assets by segment because this is not a metric used to allocate resources or evaluate segment performance. (In millions) Evernorth Health Services Cigna Healthcare Other Operations Corporate and Eliminations Total Three months ended March 31, 2023 Revenues from external customers $ 34,511 $ 11,650 $ 79 $ — $ 46,240 Intersegment revenues 1,618 963 — (2,581) Net investment income 50 143 78 6 277 Total revenues 36,179 12,756 157 (2,575) 46,517 Net realized investment results from certain equity method investments — (38) — — (38) Adjusted revenues $ 36,179 $ 12,718 $ 157 $ (2,575) $ 46,479 Income (loss) before income taxes $ 918 $ 1,077 $ 21 $ (415) $ 1,601 Pre-tax adjustments to reconcile to adjusted income from operations (Income) attributable to noncontrolling interests (42) (1) — — (43) Net realized investment losses (gains) (1) — 24 (6) — 18 Amortization of acquired intangible assets 444 15 — — 459 Special items Integration and transaction-related costs — — — 1 1 Pre-tax adjusted income (loss) from operations $ 1,320 $ 1,115 $ 15 $ (414) $ 2,036 (In millions) Evernorth Health Services Cigna Healthcare Other Operations Corporate and Eliminations Total Three months ended March 31, 2022 Revenues from external customers $ 32,289 $ 10,462 $ 841 $ — $ 43,592 Intersegment revenues 1,287 562 — (1,849) Net investment income 10 266 138 — 414 Total revenues 33,586 11,290 979 (1,849) 44,006 Net realized investment results from certain equity method investments — 103 — — 103 Adjusted revenues $ 33,586 $ 11,393 $ 979 $ (1,849) $ 44,109 Income (loss) before income taxes $ 870 $ 877 $ 215 $ (395) $ 1,567 Pre-tax adjustments to reconcile to adjusted income from operations (Income) attributable to noncontrolling interests (11) (1) (5) — (17) Net realized investment losses (gains) (1) — 406 19 — 425 Amortization of acquired intangible assets 443 15 — — 458 Special items Integration and transaction-related costs — — — 52 52 Pre-tax adjusted income (loss) from operations $ 1,302 $ 1,297 $ 229 $ (343) $ 2,485 (1) Includes the Company's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Revenue from external customers includes Pharmacy revenues, Premiums and Fees and other revenues. Prior period amounts have been retrospectively adjusted to reflect adoption of amended accounting guidance for long-duration insurance contracts, as discussed in Note 2 to the Consolidated Financial Statements. The following table presents these revenues by product, premium and service type: Three Months Ended March 31, (In millions) 2023 2022 Products (Pharmacy revenues) (ASC 606) Network revenues $ 15,748 $ 15,531 Home delivery and specialty revenues 16,025 14,699 Other revenues 1,867 1,712 Intercompany eliminations (1,496) (1,245) Total pharmacy revenues 32,144 30,697 Insurance premiums (ASC 944) Cigna Healthcare U.S. Commercial Insured 4,080 3,720 Stop loss 1,503 1,325 Other (1) 368 360 U.S. Government Medicare Advantage 2,236 2,078 Medicare Part D 415 401 Other (1), (2) Short-duration (Individual and family plans) 1,208 611 Long-duration (Individual Medicare supplement and limited benefit health products) 334 329 International Health (2) Short-duration (Group medical insurance) 700 620 Long-duration (Individual private medical insurance) 86 82 Total Cigna Healthcare 10,930 9,526 Divested International businesses — 763 Other 79 69 Intercompany eliminations 16 (2) Total premiums 11,025 10,356 Services (Fees) (ASC 606) Evernorth Health Services 2,499 1,624 Cigna Healthcare 1,606 1,496 Other Operations 1 5 Other revenues 66 16 Intercompany eliminations (1,101) (602) Total fees and other revenues 3,071 2,539 Total revenues from external customers $ 46,240 $ 43,592 (1) Other than supplemental benefits, all of U.S. Commercial and U.S. Government are short duration. (2) U.S. Government and International Health recognize premium revenue on long-duration insurance contracts (coverage greater than one year or guaranteed to be renewed at the option of the policyholder beyond one year) related to certain medicare supplement, supplemental health and life products. All other premium revenue recognized as of March 31, 2023 and March 31, 2022 is primarily related to short-duration insurance contracts.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended
Summary of Significant Accounting Policies (Policies)	Mar. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Consolidated Financial Statements include the accounts of The Cigna Group and its consolidated subsidiaries. Intercompany transactions and accounts have been eliminated in consolidation. These Consolidated Financial Statements were prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"). Certain amounts in prior years have been reclassified to conform to the current year presentation. Amounts recorded in the Consolidated Financial Statements necessarily reflect management's estimates and assumptions about medical costs, investment and receivable valuations, interest rates and other factors. Significant estimates are discussed throughout these Notes; however, actual results could differ from those estimates. The impact of a change in estimate is generally included in earnings in the period of adjustment.
Recent Accounting Pronouncements, Recently Adopted Accounting Guidance and Accounting Guidance Not Yet Adopted	Recent Accounting Pronouncements The Company's 2022 Form 10-K includes discussion of significant recent accounting pronouncements that either have impacted or may impact our financial statements in the future. The following information provides updates on recently adopted accounting pronouncements that have occurred since the Company filed its 2022 Form 10-K. There are no accounting pronouncements not yet adopted as of March 31, 2023. Targeted Improvements to the Accounting for Long-Duration Contracts ("LDTI"), Accounting Standards Update ("ASU") 2018-12 and related amendments The Cigna Group adopted LDTI January 1, 2023, which includes the following key provisions: • Changes to the measurement of the future policy benefits liability for traditional and limited-pay insurance contracts: • Assumptions used to measure cash flows (such as mortality, morbidity and lapse assumptions) are updated at least annually with the effect of changes in those assumptions remeasured retrospectively and reflected in current period net income. • Discount rate assumptions are updated quarterly based on market-level yields for low credit risk fixed income instruments ("upper-medium grade fixed-income instrument"), with any changes reflected in other comprehensive income. The upper-medium grade fixed-income instrument yield is interpreted to mean A-rated. • Deferred policy acquisition costs ("DAC") related to long-duration insurance contracts are amortized on a constant-level basis over the expected term of the related contracts. Other related deferred or capitalized balances (such as unearned revenue liability and value of business acquired) may use this simplified amortization method. • Market risk benefits ("MRB"), defined as protecting the contractholder from other-than-nominal capital market risk and exposing the insurer to that risk, are measured at fair value, with changes in fair value recognized in net income each period, except for the effect of the Company's change in nonperformance risk (own credit risk), which is recognized in other comprehensive income. • Additional disclosures, including disaggregated roll forwards for the liability for future policy benefits, market risk benefits, separate account liabilities and DAC, as well as information about significant inputs, judgments, assumptions and methods used in measurement. • The transition methods applied at adoption were: • The liability for future policy benefits was remeasured using a modified retrospective approach applied to all outstanding contracts as of the beginning of the earliest period presented and was recognized in the opening balance of retained earnings. The impact of remeasuring the future policy benefits liability for the discount rate was recorded through accumulated other comprehensive income. • DAC followed the transition method used for future policyholder benefits. • Market risk benefits were remeasured at fair value at the beginning of the earliest period presented. The difference between this fair value and carrying value was recognized in the opening balance of retained earnings, excluding the effect of the Company's change in nonperformance risk (own credit risk), which is recognized in accumulated other comprehensive income. Effects of adoption: • The new guidance applies to our long-duration insurance products predominantly within the Cigna Healthcare segment and Other Operations. • The cumulative effects of adopting the new standard were immaterial. The impacts were a decrease to January 1, 2021 Shareholders' equity of $139 million and an increase to Shareholders' net income for the year ended December 31, 2022 and December 31, 2021 of $36 million and $5 million, respectively. The corresponding impact to diluted earnings per share was an increase of $0.11 and $0.02 for the year ended December 31, 2022 and December 31, 2021, respectively. • The prior periods within our Consolidated Statements of Income, Consolidated Statements of Comprehensive Income, Consolidated Balance Sheets, Consolidated Statements of Changes in Total Equity and Consolidated Statements of Cash Flows were restated to conform to the current presentation. • Prior period balances in the Company's footnote disclosures have been updated to reflect adjustments resulting from the adoption of this standard. Refer to Note 9 to the Consolidated Financial Statements for the Company's updated accounting policies. • It is possible that our income recognition pattern could change on a prospective basis for several reasons: • Applying periodic assumption updates, versus the locked-in model, may change our timing of profit or loss recognition. • DAC amortization is on a constant level basis over the expected term of the related contracts and no longer tied to the emergence of profit on such contracts. Additionally, in December 2022, the Financial Accounting Standards Board ("FASB") published ASU 2022-05, which simplified the retrospective adoption of LDTI by permitting companies to make an accounting policy election to exclude contracts that are sold and removed from the balance sheet prior to the effective date of the standard from the retrospective adoption of LDTI. The Cigna Group made this policy election for the contracts sold in the Chubb transaction and our divested interest in a joint venture in Türkiye.
Revenue Recognition	Evernorth Health Services may also provide certain financial and performance guarantees, including a minimum level of discounts a client may receive, generic utilization rates and various service levels. Clients may be entitled to receive compensation if we fail to meet the guarantees. Actual performance is compared to the contractual guarantee for each measure throughout the period and the Company defers revenue for any estimated payouts within Accrued expenses and other liabilities (current). These estimates are adjusted and paid following the end of the annual guarantee period.
Unpaid Claims and Claims Expenses	This liability reflects estimates of the ultimate cost of claims that have been incurred but not reported, including expected development on reported claims, those that have been reported but not yet paid (reported claims in process) and other medical care expenses and services payable that are primarily comprised of accruals for incentives and other amounts payable to health care professionals and facilities.
Future Policy Benefits	Accounting Policy. Future policy benefits represent the present value of estimated future obligations, estimated using actuarial methods, for long-term insurance policies and annuity products currently in force, consisting primarily of reserves for annuity contracts, life insurance benefits, and certain supplemental health products that are guaranteed renewable beyond one year. Contracts are grouped at a level no higher than issue year, based on the original contract issue date, and at lower levels of disaggregation within each issue year for certain businesses to reflect factors including product type, plan type and currency. Management estimates these obligations based on assumptions for premiums, interest rates, mortality or morbidity, future claim adjudication expenses and surrenders. Mortality, morbidity and surrender assumptions are based on the Company's own experience and published actuarial tables, and are updated at least annually, to the extent changes in circumstances require. Interest rate assumptions are based on market-level yields for low credit risk fixed income instruments ("upper-medium grade fixed-income instrument"). For interest accretion purposes, interest rates are fixed at the year of the cohort's inception, however for purposes of liability measurement, are updated to the current rate quarterly, with all changes in the interest rate from inception to current period reported through Accumulated other comprehensive loss. For contracts issued domestically, we use observable inputs from a published spot rate curve for terms up to 30 years and extrapolate for longer terms using a constant forward rate approach. For contracts issued by foreign operating entities with functional currencies other than the U.S. dollar, we use observable inputs to approximate a risk free rate and add a credit spread adjustment to align with a low credit risk fixed income instrument. For terms beyond the last observable risk free rates, which vary by international market, we extrapolate to the ultimate forward rate assuming a constant credit spread.
Contractholder Deposit Funds	Accounting Policy. Liabilities for contractholder deposit funds primarily include deposits received from customers for investment-related and universal life products and investment earnings on their fund balances in Other Operations. These liabilities are adjusted to reflect administrative charges and, for universal life fund balances, mortality charges. Interest credited on these funds is accrued ratably over the contract period.
Market Risk Benefits	Accounting Policy. Variable annuity reinsurance liabilities are measured as MRBs at fair value, net of nonperformance risk, with fluctuations in value gross of reinsurer nonperformance risk reported in benefits expense while fluctuations in the Company's own
Reinsurance	Reinsurance and other amounts recoverable reflect amounts due from reinsurers and policyholders to cover incurred but not reported and pending claims of certain business for which the Company administers the plan benefits without any right of offset. See Note 10 to the Consolidated Financial Statements for additional information on reinsuranceThe Company's insurance subsidiaries enter into agreements with other insurance companies to limit losses from large exposures and to permit recovery of a portion of incurred losses. Reinsurance is ceded primarily in acquisition and disposition transactions when the underwriting company is not being acquired. Reinsurance does not relieve the originating insurer of liability. Therefore, reinsured liabilities must continue to be reported along with the related reinsurance recoverables. The Company regularly evaluates the financial condition of its reinsurers and monitors concentrations of its credit risk.The Company reviews its reinsurance arrangements and establishes reserves against the recoverables.Collateral levels are defined internally based on the fair value of the collateral relative to the carrying amount of the reinsurance recoverable, the frequency at which collateral is required to be replenished and the potential for volatility in the collateral's fair value.
Investments	Cigna Group's investment portfolio consists of a broad range of investments including debt securities, equity securities, commercial mortgage loans, policy loans, other long-term investments, short-term investments and derivative financial instruments.Further information about our accounting policies for investment assets can be found in Note 11 in the Company's 2022 Form 10-K.Accounting policy. Our accounting policy for debt securities (including bonds, mortgage and other asset-backed securities and preferred stocks redeemable by the investor) remains materially consistent with the policy disclosed in the Company's 2022 Form 10-K. However, with the adoption of amended accounting guidance for long-duration insurance contracts on January 1, 2023 (discussed in Note 2 to the Consolidated Financial Statements), net unrealized appreciation on debt securities supporting the Company's run-off settlement annuity business is no longer reported in Non-current insurance and contractholder liabilities but rather is reported in Accumulated other comprehensive loss. Review of declines in fair value. Management reviews impaired debt securities to determine whether a credit loss allowance is needed based on criteria that include: • severity of decline; • financial health and specific prospects of the issuer; and • changes in the regulatory, economic or general market environment of the issuer's industry or geographic region.
Derivative Financial Instruments	The Company uses derivative financial instruments to manage the characteristics of investment assets (such as duration, yield, currency and liquidity) to meet the varying demands of the related insurance and contractholder liabilities. The Company also uses derivative financial instruments to hedge the risk of changes in the net assets of certain of its foreign subsidiaries due to changes in foreign currency exchange rates and to hedge the interest rate risk of certain long-term debt.Please refer to the Company's 2022 Form 10-K for further discussion of the types of derivative financial instruments and associated accounting policies.
Fair Value Measurements	The Company carries certain financial instruments at fair value in the financial statements including debt securities, certain equity securities, short-term investments and derivatives. Other financial instruments are measured at fair value only under certain conditions, such as when impaired or when there are observable price changes for equity securities with no readily determinable fair value. Fair value is defined as the price at which an asset could be exchanged in an orderly transaction between market participants at the balance sheet date. A liability's fair value is defined as the amount that would be paid to transfer the liability to a market participant, not the amount that would be paid to settle the liability with the creditor. The Company's financial assets and liabilities carried at fair value have been classified based upon a hierarchy defined by GAAP. The hierarchy gives the highest ranking to fair values determined using unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest ranking to fair values determined using methodologies and models with unobservable inputs (Level 3). An asset's or a liability's classification is based on the lowest level of input that is significant to its measurement. For example, a financial asset or liability carried at fair value would be classified in Level 3 if unobservable inputs were significant to the instrument's fair value, even though the measurement may be derived using inputs that are both observable (Levels 1 and 2) and unobservable (Level 3). Level 3 Financial Assets and Financial Liabilities Certain inputs for instruments classified in Level 3 are unobservable (supported by little or no market activity) and significant to their resulting fair value measurement. Unobservable inputs reflect the Company's best estimate of what hypothetical market participants would use to determine a transaction price for the asset or liability at the reporting date. Additionally, as discussed in Note 9 to the Consolidated Financial Statements, the Company classifies variable annuity assets and liabilities in Level 3 of the fair value hierarchy. Total gains and losses included in Shareholders' net income in the tables above are reflected in the Consolidated Statements of Income as Net realized investment losses and Net investment income. Gains and losses included in Other comprehensive loss, net of tax in the tables above are reflected in Net unrealized appreciation (depreciation) on securities and derivatives in the Consolidated Statements of Comprehensive Income.
Separate Accounts	Separate Accounts The investment income and fair value gains and losses of Separate account assets generally accrue directly to the contractholders and, together with their deposits and withdrawals, are excluded from the Company's Consolidated Statements of Income and Cash Flows.
Variable Interest Entities	For details of our accounting policy for variable interest entities and the composition of variable interest entities with which the Company is involved, refer to Note 13 in the Company's 2022 Form 10-K.
Guarantees	Financial Guarantees: Retiree and Life Insurance BenefitsThe Company guarantees that separate account assets will be sufficient to pay certain life insurance or retiree benefits. For the majority of these benefits, the sponsoring employers are primarily responsible for ensuring that assets are sufficient to pay these benefits and are required to maintain assets that exceed a certain percentage of benefit obligations. If employers fail to do so, the Company or an affiliate of the buyer of the retirement benefits business has the right to redirect the management of the related assets to provide for benefit payments.An additional liability is established if management believes that the Company will be required to make payments under the guarantees;Separate account assets supporting these guarantees are classified in Levels 1 and 2 of the GAAP fair value hierarchy.Certain Other GuaranteesThe Company had indemnification obligations as of March 31, 2023 in connection with acquisition and disposition transactions. These indemnification obligations are triggered by the breach of representations or covenants provided by the Company, such as representations for the presentation of financial statements, filing of tax returns, compliance with law or identification of outstanding litigation. These obligations are typically subject to various time limitations, defined by the contract or by operation of law, such as statutes of limitation. In some cases, the maximum potential amount due is subject to contractual limitations based on a percentage of the transaction purchase price, while in other cases limitations are not specified or applicable. The Company does not believe that it is possible to determine the maximum potential amount due under these obligations because not all amounts due under these indemnification obligations are subject to limitation.Guaranty Fund AssessmentsThe Company operates in a regulatory environment that may require its participation in assessments under state insurance guaranty association laws. The Company's exposure to assessments for certain obligations of insolvent insurance companies to policyholders and claimants is based on its share of business written in the relevant jurisdictions.
Segment Information	Intersegment revenues primarily reflect pharmacy and care services transactions between the Evernorth Health Services and Cigna Healthcare segments.The Company uses "pre-tax adjusted income (loss) from operations" and "adjusted revenues" as its principal financial measures of segment operating performance because management believes these metrics best reflect the underlying results of business operations and permit analysis of trends in underlying revenue, expenses and profitability. We define pre-tax adjusted income from operations as income before income taxes excluding pre-tax income (loss) attributable to noncontrolling interests, net realized investment results, amortization of acquired intangible assets, and special items. The Cigna Group's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting are also excluded. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. Adjusted income (loss) from operations is measured on an after-tax basis for consolidated results and on a pre-tax basis for segment results. The Company defines adjusted revenues as total revenues excluding the following adjustments: special items and The Cigna Group's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting. Special items are matters that management believes are not representative of the underlying results of operations due to their nature or size. We exclude these items from this measure because management believes they are not indicative of past or future underlying performance of the business.

Accounts Receivable, Net (Table

Accounts Receivable, Net (Tables)	3 Months Ended
Accounts Receivable, Net (Tables)	Mar. 31, 2023
Receivables [Abstract]
Accounts Receivable, Net	The following amounts were included within Accounts receivable, net: (In millions) March 31, 2023 December 31, 2022 Noninsurance customer receivables $ 7,845 $ 6,899 Pharmaceutical manufacturers receivables 7,128 7,108 Insurance customer receivables 2,467 2,963 Other receivables 264 248 Total $ 17,704 $ 17,218

Earnings Per Share (Tables)

Earnings Per Share (Tables)	3 Months Ended
Earnings Per Share (Tables)	Mar. 31, 2023
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings Per Share	Basic and diluted earnings per share were computed as follows: Three Months Ended March 31, 2023 March 31, 2022 (Shares in thousands, dollars in millions, except per share amounts) Basic Effect of Diluted Basic Effect of Diluted Shareholders' net income $ 1,267 $ 1,267 $ 1,197 $ 1,197 Shares: Weighted average 295,706 295,706 318,487 318,487 Common stock equivalents 3,293 3,293 2,795 2,795 Total shares 295,706 3,293 298,999 318,487 2,795 321,282 Earnings per share $ 4.28 $ (0.04) $ 4.24 $ 3.76 $ (0.03) $ 3.73 Amounts reflected above for the three months ended March 31, 2022 have been restated to reflect the impact of adopting amended accounting guidance for long-duration insurance contracts (discussed in Note 2 to the Consolidated Financial Statements).
Outstanding Employee Stock Options Not Included in the Computation of Diluted Earnings Per Share	The following outstanding employee stock options were not included in the computation of diluted earnings per share because their effect was anti-dilutive: Three Months Ended March 31, (In millions) 2023 2022 Anti-dilutive options 0.9 2.8

Debt (Tables)

Debt (Tables)	3 Months Ended
Debt (Tables)	Mar. 31, 2023
Debt Disclosure [Abstract]
Outstanding Amounts of Debt and Finance Leases	The outstanding amounts of debt, net of issuance costs, discounts or premiums, and finance leases were as follows: (In millions) March 31, 2023 December 31, 2022 Short-term debt $17 million, 8.300% Notes due January 2023 — 17 $63 million, 7.650% Notes due March 2023 — 63 $700 million, Floating Rate Notes due July 2023 700 700 $1,000 million, 3.000% Notes due July 2023 996 994 $1,187 million, 3.750% Notes due July 2023 1,187 1,186 $500 million, 0.613% Notes due March 2024 499 — Other, including finance leases 36 33 Total short-term debt $ 3,418 $ 2,993 Long-term debt $500 million, 0.613% Notes due March 2024 — 499 $1,000 million, 3.500% Notes due June 2024 992 990 $900 million, 3.250% Notes due April 2025 (1) 878 872 $2,200 million, 4.125% Notes due November 2025 2,195 2,195 $1,500 million, 4.500% Notes due February 2026 1,503 1,503 $800 million, 1.250% Notes due March 2026 797 797 $700 million, 5.685% Notes due March 2026 697 — $1,500 million, 3.400% Notes due March 2027 1,440 1,436 $259 million, 7.875% Debentures due May 2027 259 259 $600 million, 3.050% Notes due October 2027 597 597 $3,800 million, 4.375% Notes due October 2028 3,785 3,785 $1,500 million, 2.400% Notes due March 2030 1,492 1,492 $1,500 million, 2.375% Notes due March 2031 (1) 1,398 1,380 $45 million, 8.080% Step Down Notes due January 2033 (2) 45 45 $800 million, 5.400% Notes due March 2033 794 — $190 million, 6.150% Notes due November 2036 190 190 $2,200 million, 4.800% Notes due August 2038 2,192 2,192 $750 million, 3.200% Notes due March 2040 743 743 $121 million, 5.875% Notes due March 2041 119 119 $448 million, 6.125% Notes due November 2041 488 488 $317 million, 5.375% Notes due February 2042 315 315 $1,500 million, 4.800% Notes due July 2046 1,466 1,466 $1,000 million, 3.875% Notes due October 2047 989 989 $3,000 million, 4.900% Notes due December 2048 2,969 2,968 $1,250 million, 3.400% Notes due March 2050 1,236 1,236 $1,500 million, 3.400% Notes due March 2051 1,478 1,478 Other, including finance leases 67 66 Total long-term debt $ 29,124 $ 28,100 (1) The Company has entered into interest rate swap contracts hedging a portion of these fixed-rate debt instruments. See Note 11 in the Company's 2022 Form 10-K for further information about the Company's interest rate risk management and these derivative instruments. (2) Interest rate step down to 8.080% effective January 15, 2023.
Summary of Debt Issuances	On March 7, 2023, the Company issued $1.5 billion of new senior notes. The proceeds of this issuance will be used for general corporate purposes, and may include repayment of outstanding debt securities. Interest on this debt is paid semi-annually. Principal Maturity Date Interest Rate Net Proceeds $700 million (1) March 15, 2026 5.685% $698 million $800 million (2) March 15, 2033 5.400% $796 million (1) Redeemable at any time discounted at the U.S. Treasury rate plus 20 basis points. Redeemable at par on or after March 15, 2024.

Common and Preferred Stock (Tab

Common and Preferred Stock (Tables)	3 Months Ended
Common and Preferred Stock (Tables)	Mar. 31, 2023
Equity [Abstract]
Dividend Payments	The following table provides details of the Company's dividend payments: Record Date Payment Date Amount per Share Total Amount Paid (in millions) 2023 March 8, 2023 March 23, 2023 $1.23 $368 2022 March 9, 2022 March 24, 2022 $1.12 $357

Insurance and Contractholder _2

Insurance and Contractholder Liabilities (Tables)	3 Months Ended
Insurance and Contractholder Liabilities (Tables)	Mar. 31, 2023
Insurance Loss Reserves [Abstract]
Summary of Insurance and Contractholder Liabilities, Activity in the Unpaid Claims Liability and Liability Details for Unpaid Claims and Claim Expenses	The Company's insurance and contractholder liabilities were comprised of the following: March 31, 2023 December 31, 2022 March 31, 2022 (In millions) Current Non-current Total Current Non-current Total Total Unpaid claims and claim expenses Cigna Healthcare $ 4,880 $ 79 $ 4,959 $ 4,117 $ 59 $ 4,176 $ 4,491 Other Operations 97 175 272 107 177 284 744 Future policy benefits Cigna Healthcare 59 542 601 43 544 587 681 Other Operations 290 3,341 3,631 150 3,442 3,592 7,981 Contractholder deposit funds Cigna Healthcare 12 151 163 14 157 171 181 Other Operations 361 6,309 6,670 351 6,358 6,709 6,843 Market risk benefits 48 1,172 1,220 51 1,217 1,268 1,558 Unearned premiums 1,419 21 1,440 576 22 598 1,030 Total 23,509 Insurance and contractholder liabilities classified as Liabilities of businesses held for sale (1) (4,562) Total insurance and contractholder liabilities $ 7,166 $ 11,790 $ 18,956 $ 5,409 $ 11,976 $ 17,385 $ 18,947 (1) Amounts classified as Liabilities of businesses held for sale primarily include $3.7 billion of Future policy benefits, $0.4 billion of Unpaid claims and $0.4 billion of Unearned premiums as of March 31, 2022. Activity, net of intercompany transactions, in the unpaid claims liability for the Cigna Healthcare segment was as follows: Three Months Ended (In millions) March 31, 2023 March 31, 2022 Beginning balance $ 4,176 $ 4,261 Less: Reinsurance and other amounts recoverable 221 261 Beginning balance, net 3,955 4,000 Incurred costs related to: Current year 9,041 8,024 Prior years (144) (276) Total incurred 8,897 7,748 Paid costs related to: Current year 5,316 4,634 Prior years 2,795 2,822 Total paid 8,111 7,456 Ending balance, net 4,741 4,292 Add: Reinsurance and other amounts recoverable 218 199 Ending balance $ 4,959 $ 4,491
Variances in Incurred Costs Related to Prior Years' Unpaid Claims and Claims Expenses	Variances in incurred costs related to prior years' unpaid claims and claim expenses that resulted from the differences between actual experience and the Company's key assumptions were as follows: Three Months Ended March 31, 2023 March 31, 2022 (Dollars in millions) $ % (1) $ % (2) Actual completion factors $ 1 — % $ 99 0.3 % Medical cost trend 143 0.5 177 0.6 Total favorable variance $ 144 0.5 % $ 276 0.9 % (1) Percentage of current year incurred costs as reported for the year ended December 31, 2022. (2) Percentage of current year incurred costs as reported for the year ended December 31, 2021.
Future Policy Benefit Activity	The weighted average interest rates applied and duration for future policy benefits in the Cigna Healthcare segment, consisting primarily of supplemental health products including individual Medicare supplement, limited benefit health products and individual private medical insurance, were as follows: As of March 31, 2023 March 31, 2022 Interest accretion rate 2.59 % 2.64 % Current discount rate 5.29 % 4.90 % Weighted average duration 8.05 years 7.45 years Three Months Ended (In millions) March 31, 2023 March 31, 2022 Present value of expected net premiums Beginning balance $ 8,557 $ 9,314 Reversal of effect of beginning of period discount rate assumptions 1,537 (367) Effect of assumption changes and actual variances from expected experience — — Issuances and lapses 306 143 Net premiums collected (326) (310) Interest and other (1) 56 46 Ending balance at original discount rate 10,130 8,826 Effect of end of period discount rate assumptions (1,312) (376) Ending balance (2) $ 8,818 $ 8,450 Present value of expected policy benefits Beginning balance $ 8,945 $ 9,794 Reversal of effect of discount rate assumptions 1,611 (379) Effect of assumption changes and actual variances from expected experience — — Issuances and lapses 307 215 Benefit payments (326) (385) Interest and other (1) 58 52 Ending balance at original discount rate 10,595 9,297 Effect of discount rate assumptions (1,378) (392) Ending balance (3) $ 9,217 $ 8,905 Liability for future policy benefits $ 399 $ 455 Other (4) 202 226 Total liability for future policy benefits (5) $ 601 $ 681 (1) Includes the foreign exchange rate impact of translating from transactional and functional currency to United States dollar and the impact of flooring the liability at zero. The flooring impact is calculated at the cohort level after discounting the reserves at the current discount rate. (2) As of March 31, 2023 and March 31, 2022, respectively, undiscounted expected future gross premiums were $17.6 billion and $13.5 billion. As of March 31, 2023 and March 31, 2022, respectively, discounted expected future gross premiums were $12.5 billion and $10.7 billion. (3) As of March 31, 2023 and March 31, 2022, respectively, undiscounted expected future policy benefits were $12.8 billion and $11.2 billion. (4) The liability for future policyholder benefits includes immaterial businesses shown as reconciling items above, most of which are in run-off. (5) $154 million and $171 million of reinsurance recoverable asset reported in the Consolidated Balance Sheets as of March 31, 2023 and March 31, 2022, respectively, relate to the liability for future policy benefits. The weighted average interest rates applied and duration for future policy benefits in Other Operations, consisting of annuity and life insurance products, were as follows: As of March 31, 2023 March 31, 2022 Interest accretion rate 5.64 % 5.64 % Current discount rate 4.95 % 3.59 % Weighted average duration 11.7 years 13.9 years
Summary of Market Risk Benefit	Market risk benefits activity was as follows: Three Months Ended (Dollars in millions) March 31, 2023 March 31, 2022 Balance, beginning of year $ 1,268 $ 1,824 Balance, beginning of year, before the effect of nonperformance risk (own credit risk) 1,379 1,949 Changes due to expected run-off (6) (19) Changes due to capital markets versus expected (41) (271) Changes due to policyholder behavior versus expected 6 (9) Assumption changes (33) 39 Balance, end of year, before the effect of changes in nonperformance risk (own credit risk) 1,305 1,689 Nonperformance risk (own credit risk), end of period (85) (131) Balance, end of period $ 1,220 $ 1,558 Reinsured market risk benefit, end of period $ 1,301 $ 1,681 (In millions) Reinsurer (1) March 31, 2023 December 31, 2022 Collateral and Other Terms at March 31, 2023 Berkshire $ 1,043 $ 1,116 90% were secured by assets in a trust. Sun Life Assurance Company of Canada 117 115 Liberty Re (Bermuda) Ltd. 128 128 100% were secured by assets in a trust. SCOR SE 35 39 70% were secured by a letter of credit. Market risk benefits (2) $ 1,323 $ 1,398 (1) All reinsurers are rated A- equivalent and higher by an NRSRO. (2) Includes IBNR and outstanding claims of $25 million offset by premium due of $3 million. These amounts are excluded from market risk benefits at March 31, 2023 in Note 9 and Note 10A to the Consolidated Financial Statements. At December 31, 2022, IBNR and outstanding claims of $27 million offset by premium due of $3 million were excluded from the market risk benefits as restated due to the adoption of LDTI.
Account Value, Net Amount at Risk and the Number of Contractholders for Guarantees Assumed in the Event of Death	The following table presents the net amount at risk and the average attained age of contractholders (weighted by exposure) for contracts assumed by the Company. The net amount at risk is the amount the Company would have to pay to contractholders if all deaths or annuitizations occurred as of the earliest possible date in accordance with the insurance contract. The Company should be reimbursed in full for these payments unless the Berkshire reinsurance limit is exceeded, as discussed further in Note 10 to the Consolidated Financial Statements. (Dollars in millions, excludes impact of reinsurance ceded) March 31, 2023 March 31, 2022 Net amount at risk $ 2,183 $ 1,892 Average attained age of contractholders (weighted by exposure) 75.4 years 76.4 years

Reinsurance (Tables)

Reinsurance (Tables)	3 Months Ended
Reinsurance (Tables)	Mar. 31, 2023
Reinsurance Disclosures [Abstract]
Reinsurance Recoverables by Range of External Credit Rating and Collateral Level	The Company's reinsurance recoverables as of March 31, 2023 are presented at amount due by range of external credit rating and collateral level in the following table, with reinsurance recoverables that are market risk benefits separately presented at fair value: (In millions) Fair value of collateral contractually required to meet or exceed carrying value of recoverable Collateral provisions exist that may mitigate risk of credit loss (3) No collateral Total Ongoing Operations A- equivalent and higher current ratings (1) $ — $ — $ 94 $ 94 BBB- to BBB+ equivalent current credit ratings (1) — — 59 59 Not rated 142 5 63 210 Total recoverables related to ongoing operations (2) 142 5 216 363 Acquisition, disposition or run-off activities BBB+ equivalent and higher current ratings (1) Lincoln National Life and Lincoln Life & Annuity of New York — 2,750 — 2,750 Empower Annuity Insurance Company — — 133 133 Prudential Insurance Company of America 380 — — 380 Life Insurance Company of North America — 386 — 386 Other 187 25 15 227 Not rated — 9 3 12 Total recoverables related to acquisition, disposition or run-off activities 567 3,170 151 3,888 Total reinsurance recoverables before market risk benefits $ 709 $ 3,175 $ 367 $ 4,251 Allowance for uncollectible reinsurance (35) Market risk benefits (4) 1,301 Total reinsurance recoverables (2) $ 5,517 (1) Certified by a Nationally Recognized Statistical Rating Organization ("NRSRO"). (2) Includes $231 million of current reinsurance recoverables that are reported in Other current assets. (3) Includes collateral provisions requiring the reinsurer to fully collateralize its obligation if its external credit rating is downgraded to a specified level. (4) Total Berkshire and certain Other recoverables reflected under acquisition, disposition or run-off activities in the Company's 2022 Form 10-K that relate to the Company’s variable annuity reinsurance products discussed in section B below are now reported at fair market value as MRBs, as further discussed in Note 9 to the Consolidated Financial Statements. At December 31, 2022, we reported $711 million related to these recoverables related to the GMDB variable annuity reinsurance product. The restated December 31, 2022 variable annuity reinsurance recoverable balance is $1.4 billion, which also includes the GMIB variable annuity reinsurance product that was classified in Other assets prior to the adoption of LDTI.
Reinsurance Recoverables for Variable Annuity Business	Market risk benefits activity was as follows: Three Months Ended (Dollars in millions) March 31, 2023 March 31, 2022 Balance, beginning of year $ 1,268 $ 1,824 Balance, beginning of year, before the effect of nonperformance risk (own credit risk) 1,379 1,949 Changes due to expected run-off (6) (19) Changes due to capital markets versus expected (41) (271) Changes due to policyholder behavior versus expected 6 (9) Assumption changes (33) 39 Balance, end of year, before the effect of changes in nonperformance risk (own credit risk) 1,305 1,689 Nonperformance risk (own credit risk), end of period (85) (131) Balance, end of period $ 1,220 $ 1,558 Reinsured market risk benefit, end of period $ 1,301 $ 1,681 (In millions) Reinsurer (1) March 31, 2023 December 31, 2022 Collateral and Other Terms at March 31, 2023 Berkshire $ 1,043 $ 1,116 90% were secured by assets in a trust. Sun Life Assurance Company of Canada 117 115 Liberty Re (Bermuda) Ltd. 128 128 100% were secured by assets in a trust. SCOR SE 35 39 70% were secured by a letter of credit. Market risk benefits (2) $ 1,323 $ 1,398 (1) All reinsurers are rated A- equivalent and higher by an NRSRO. (2) Includes IBNR and outstanding claims of $25 million offset by premium due of $3 million. These amounts are excluded from market risk benefits at March 31, 2023 in Note 9 and Note 10A to the Consolidated Financial Statements. At December 31, 2022, IBNR and outstanding claims of $27 million offset by premium due of $3 million were excluded from the market risk benefits as restated due to the adoption of LDTI.

Investments (Tables)

Investments (Tables)	3 Months Ended
Investments (Tables)	Mar. 31, 2023
Investments [Abstract]
Investments by category and current or long-term classification	The following table summarizes the Company's investments by category and current or long-term classification: March 31, 2023 December 31, 2022 (In millions) Current Long-term Total Current Long-term Total Debt securities $ 616 $ 9,293 $ 9,909 $ 654 $ 9,218 $ 9,872 Equity securities 51 3,069 3,120 45 577 622 Commercial mortgage loans 106 1,501 1,607 67 1,547 1,614 Policy loans — 1,211 1,211 — 1,218 1,218 Other long-term investments — 3,936 3,936 — 3,728 3,728 Short-term investments 141 — 141 139 — 139 Total $ 914 $ 19,010 $ 19,924 $ 905 $ 16,288 $ 17,193
Debt Securities by Contractual Maturity	The amortized cost and fair value by contractual maturity periods for debt securities were as follows as of March 31, 2023: (In millions) Amortized Fair Due in one year or less $ 638 $ 630 Due after one year through five years 3,972 3,752 Due after five years through ten years 3,227 2,915 Due after ten years 2,450 2,268 Mortgage and other asset-backed securities 381 344 Total $ 10,668 $ 9,909
Gross Unrealized Appreciation (Depreciation) on Debt Securities	Gross unrealized appreciation (depreciation) on debt securities by type of issuer is shown below: (In millions) Amortized Allowance for Credit Loss Unrealized Unrealized Fair March 31, 2023 Federal government and agency $ 276 $ — $ 29 $ (8) $ 297 State and local government 42 — — (1) 41 Foreign government 373 — 16 (18) 371 Corporate 9,596 (41) 124 (823) 8,856 Mortgage and other asset-backed 381 — 1 (38) 344 Total $ 10,668 $ (41) $ 170 $ (888) $ 9,909 December 31, 2022 Federal government and agency $ 292 $ — $ 32 $ (12) $ 312 State and local government 43 — — (2) 41 Foreign government 375 — 11 (21) 365 Corporate 9,742 (44) 89 (981) 8,806 Mortgage and other asset-backed 390 — 1 (43) 348 Total $ 10,842 $ (44) $ 133 $ (1,059) $ 9,872
Summary of Debt Securities with a Decline in Fair Value	The table below summarizes debt securities with a decline in fair value from amortized cost for which an allowance for credit losses has not been recorded, by investment grade and the length of time these securities have been in an unrealized loss position. Unrealized depreciation on these debt securities is primarily due to declines in fair value resulting from increasing interest rates since these securities were purchased. March 31, 2023 December 31, 2022 (Dollars in millions) Fair Amortized Unrealized Number Fair Amortized Unrealized Number One year or less Investment grade $ 3,176 $ 3,362 $ (186) 1,019 $ 5,533 $ 6,127 $ (594) 1,659 Below investment grade 353 371 (18) 936 887 964 (77) 1,287 More than one year Investment grade 3,222 3,808 (586) 1,035 1,151 1,487 (336) 462 Below investment grade 682 780 (98) 770 330 382 (52) 369 Total $ 7,433 $ 8,321 $ (888) 3,760 $ 7,901 $ 8,960 $ (1,059) 3,777
Equity Security Investments	The following table provides the values of the Company's equity security investments as of March 31, 2023 and December 31, 2022: March 31, 2023 December 31, 2022 (In millions) Cost Carrying Value Cost Carrying Value Equity securities with readily determinable fair values $ 680 $ 91 $ 673 $ 138 Equity securities with no readily determinable fair value 2,926 3,029 380 484 Total $ 3,606 $ 3,120 $ 1,053 $ 622
Summary of the Credit Risk Profile of the Commercial Mortgage Loan Portfolio	The following table summarizes the credit risk profile of the Company's commercial mortgage loan portfolio: (Dollars in millions) March 31, 2023 December 31, 2022 Loan-to-Value Ratio Carrying Value Average Debt Service Coverage Ratio Average Loan-to-Value Ratio Carrying Value Average Debt Service Coverage Ratio Average Loan-to-Value Ratio Below 60% $ 912 2.11 $ 901 2.12 60% to 79% 504 1.73 564 1.73 80% to 100% 191 1.32 149 1.17 Total $ 1,607 1.89 60 % $ 1,614 1.89 60 %
Carrying Value Information for Other Long-Term Investments	The following table provides the carrying value information for these investments: Carrying Value as of (In millions) March 31, 2023 December 31, 2022 Real estate investments $ 1,434 $ 1,319 Securities partnerships 2,259 2,166 Other 243 243 Total $ 3,936 $ 3,728
Realized Gains and Losses on Investments	The following realized gains and losses on investments exclude realized gains and losses attributed to the Company's separate accounts because those gains and losses generally accrue directly to separate account policyholders: Three Months Ended March 31, (In millions) 2023 2022 Net realized investment (losses), excluding credit loss expense and asset write-downs $ (51) $ (322) Credit loss recoveries 3 — Other investment asset write-downs (8) — Net realized investment (losses), before income taxes $ (56) $ (322)

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	3 Months Ended
Fair Value Measurements (Tables)	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Financial Assets and Financial Liabilities Carried at Fair Value	The following table provides information about the Company's financial assets and liabilities carried at fair value. Further information regarding insurance assets and liabilities carried at fair value is provided in Note 9E to the Consolidated Financial Statements. Separate account assets are also recorded at fair value on the Company's Consolidated Balance Sheets and are reported separately in the Separate Accounts section below as gains and losses related to these assets generally accrue directly to contractholders: (In millions) Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total March 31, 2023 December 31, 2022 March 31, 2023 December 31, 2022 March 31, 2023 December 31, 2022 March 31, 2023 December 31, 2022 Financial assets at fair value Debt securities Federal government and agency $ 151 $ 147 $ 146 $ 165 $ — $ — $ 297 $ 312 State and local government — — 41 41 — — 41 41 Foreign government — — 371 365 — — 371 365 Corporate — — 8,421 8,394 435 412 8,856 8,806 Mortgage and other asset-backed — — 309 313 35 35 344 348 Total debt securities 151 147 9,288 9,278 470 447 9,909 9,872 Equity securities (1) 6 6 84 132 1 — 91 138 Short-term investments — — 141 139 — — 141 139 Derivative assets — — 206 230 1 1 207 231 (1) Excludes certain equity securities that have no readily determinable fair value.
Fair Value and Significant Unobservable Inputs Used in Pricing Debt Securities	The following table summarizes the fair value and significant unobservable inputs that were developed directly by the Company and used in pricing these debt securities. The range and weighted average basis point ("bps") amounts for liquidity reflect the Company's best estimates of the unobservable adjustments a market participant would make to calculate these fair values. Fair Value as of Unobservable Adjustment Range (Weighted Average by Quantity) as of (Fair value in millions) March 31, 2023 December 31, 2022 Unobservable input March 31, 2023 March 31, 2023 December 31, 2022 Debt securities Corporate and government debt securities $ 433 $ 412 Liquidity 60 - 1060 (300) bps 60 - 1060 (270) bps Mortgage and other asset-backed securities 35 35 Liquidity 105 - 520 (310) bps 110 - 520 (310) bps Other debt securities 2 — Total Level 3 debt securities $ 470 $ 447
Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value	The following table summarizes the changes in financial assets and financial liabilities classified in Level 3. Gains and losses reported in the table may include net changes in fair value that are attributable to both observable and unobservable inputs. For the Three Months Ended (In millions) 2023 2022 Debt and Equity Securities Beginning balance $ 447 $ 796 Gains included in Shareholders' net income 1 12 Gains (losses) included in Other comprehensive loss 5 (15) Losses required to adjust future policy benefits for settlement annuities (1) — (12) Purchases, sales and settlements Purchases 4 49 Settlements (9) (81) Total purchases, sales and settlements (5) (32) Transfers into/(out of) Level 3 Transfers into Level 3 39 101 Transfers out of Level 3 (16) (164) Total transfers into/(out of) Level 3 23 (63) Ending balance $ 471 $ 686 Total gains included in Shareholders' net income attributable to instruments held at the reporting date $ 1 $ — Change in unrealized gain or (loss) included in Other comprehensive loss for assets held at the end of the reporting period $ 5 $ (13) (1) Amounts do not accrue to shareholders.
Fair Values of Separate Account Assets	Fair values of Separate account assets were as follows: Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total (In millions) March 31, 2023 December 31, 2022 March 31, 2023 December 31, 2022 March 31, 2023 December 31, 2022 March 31, 2023 December 31, 2022 Guaranteed separate accounts (See Note 16) $ 213 $ 203 $ 349 $ 382 $ — $ — $ 562 $ 585 Non-guaranteed separate accounts (1) 221 211 5,586 5,522 213 203 6,020 5,936 Subtotal $ 434 $ 414 $ 5,935 $ 5,904 $ 213 $ 203 6,582 6,521 Non-guaranteed separate accounts priced at net asset value ("NAV") as a practical expedient (1) 758 757 Total $ 7,340 $ 7,278 (1) Non-guaranteed separate accounts include $4.0 billion as of March 31, 2023 and December 31, 2022 in assets supporting the Company's pension plans, including $0.2 billion classified in Level 3 as of March 31, 2023 and December 31, 2022.
Additional Information on Separate Account Assets Priced at NAV	Separate account investments in securities partnerships, real estate and hedge funds are generally valued based on the separate account's ownership share of the equity of the investee (NAV as a practical expedient), including changes in the fair values of its underlying investments. Substantially all of these assets support the Company's pension plans. The following table provides additional information on these investments: Fair Value as of Unfunded Commitment as of March 31, 2023 Redemption Frequency Redemption Notice (In millions) March 31, 2023 December 31, 2022 Securities partnerships $ 467 $ 451 $ 228 Not applicable Not applicable Real estate funds 287 302 — Quarterly 30 - 90 days Hedge funds 4 4 — Up to annually, varying by fund 30 - 90 days Total $ 758 $ 757 $ 228
Fair Value Disclosures for Financial Instruments Not Carried at Fair Value	The following table includes the Company's financial instruments not recorded at fair value but for which fair value disclosure is required. In addition to universal life products and finance leases, financial instruments that are carried in the Company's Consolidated Balance Sheets at amounts that approximate fair value are excluded from the following table: Classification in Fair Value Hierarchy March 31, 2023 December 31, 2022 (In millions) Fair Value Carrying Value Fair Value Carrying Value Commercial mortgage loans Level 3 $ 1,509 $ 1,607 $ 1,491 $ 1,614 Long-term debt, including current maturities, excluding finance leases Level 2 $ 30,679 $ 32,439 $ 28,653 $ 30,994

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
Segment Information (Tables)	Mar. 31, 2023
Segment Reporting [Abstract]
Summarized Segment Financial Information	Effective January 1, 2023, we adopted amended accounting guidance for long-duration insurance contracts. See Note 2 to the Consolidated Financial Statements for further information. Prior period summarized segment information has been retrospectively adjusted to conform to this new basis of accounting. Summarized segment financial information was as follows: (In millions) Evernorth Health Services Cigna Healthcare Other Operations Corporate and Eliminations Total Three months ended March 31, 2023 Revenues from external customers $ 34,511 $ 11,650 $ 79 $ — $ 46,240 Intersegment revenues 1,618 963 — (2,581) Net investment income 50 143 78 6 277 Total revenues 36,179 12,756 157 (2,575) 46,517 Net realized investment results from certain equity method investments — (38) — — (38) Adjusted revenues $ 36,179 $ 12,718 $ 157 $ (2,575) $ 46,479 Income (loss) before income taxes $ 918 $ 1,077 $ 21 $ (415) $ 1,601 Pre-tax adjustments to reconcile to adjusted income from operations (Income) attributable to noncontrolling interests (42) (1) — — (43) Net realized investment losses (gains) (1) — 24 (6) — 18 Amortization of acquired intangible assets 444 15 — — 459 Special items Integration and transaction-related costs — — — 1 1 Pre-tax adjusted income (loss) from operations $ 1,320 $ 1,115 $ 15 $ (414) $ 2,036 (In millions) Evernorth Health Services Cigna Healthcare Other Operations Corporate and Eliminations Total Three months ended March 31, 2022 Revenues from external customers $ 32,289 $ 10,462 $ 841 $ — $ 43,592 Intersegment revenues 1,287 562 — (1,849) Net investment income 10 266 138 — 414 Total revenues 33,586 11,290 979 (1,849) 44,006 Net realized investment results from certain equity method investments — 103 — — 103 Adjusted revenues $ 33,586 $ 11,393 $ 979 $ (1,849) $ 44,109 Income (loss) before income taxes $ 870 $ 877 $ 215 $ (395) $ 1,567 Pre-tax adjustments to reconcile to adjusted income from operations (Income) attributable to noncontrolling interests (11) (1) (5) — (17) Net realized investment losses (gains) (1) — 406 19 — 425 Amortization of acquired intangible assets 443 15 — — 458 Special items Integration and transaction-related costs — — — 52 52 Pre-tax adjusted income (loss) from operations $ 1,302 $ 1,297 $ 229 $ (343) $ 2,485 (1) Includes the Company's share of certain realized investment results of its joint ventures reported in the Cigna Healthcare segment using the equity method of accounting.

Description of Business (Detail

Description of Business (Details) $ in Billions	Jul. 01, 2022 USD ($)
International life, accident, supplemental benefits businesses sold to Chubb \| Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sale price	$ 5.4

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended			12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022		Dec. 31, 2022		Dec. 31, 2021		Dec. 31, 2020
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Decrease to shareholders' equity	$ (44,518)	$ (46,145)		$ (44,688)	[1],[2]	$ (46,976)	[2]
Increase to shareholders' net income	$ 1,267	$ 1,197	[3]
Increase to diluted earnings per share (in dollars per share)	$ 4.24	$ 3.73	[3]
Revision of Prior Period, Accounting Standards Update, Adjustment
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Increase to shareholders' net income				$ 36		$ 5
Increase to diluted earnings per share (in dollars per share)				$ 0.11		$ 0.02
Adjustment upon Adoption
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Decrease to shareholders' equity								$ 139
Pharmacy Benefits Management Services \| Guarantees
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Performance guarantee liability	$ 1,500			$ 1,300

[1]Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.[2]Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements to the Consolidated Financial Statements for further information.[3]Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.

Accounts Receivable, Net - Summ

Accounts Receivable, Net - Summary of Accounts Receivable, Net (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Receivables [Abstract]
Noninsurance customer receivables	$ 7,845	$ 6,899
Pharmaceutical manufacturers receivables	7,128	7,108
Insurance customer receivables	2,467	2,963
Other receivables	264	248
Accounts receivable, net	$ 17,704	$ 17,218	[1]

[1]Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.

Accounts Receivable, Net - Narr

Accounts Receivable, Net - Narrative (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Receivables [Abstract]
Allowance for receivables, current	$ 2,100	$ 1,900
Allowance for current expected credit losses on accounts receivable	$ 87	$ 86

Supplier Finance Program (Detai

Supplier Finance Program (Details) - USD ($) $ in Millions	3 Months Ended
Supplier Finance Program (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Payment term (in months)	1 month
Outstanding payment obligations, current	$ 1,500	$ 1,300
Outstanding payment obligations, current, voluntarily elected by suppliers to be sold to the financial institution	$ 324

Mergers, Acquisitions and Div_2

Mergers, Acquisitions and Divestitures - Narrative (Details) - USD ($) $ in Millions		3 Months Ended
	Jul. 01, 2022	Mar. 31, 2023	Mar. 31, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Integration and transaction-related costs, pre-tax		$ 1	$ 52
Integration and transaction-related costs, after-tax		$ 1	$ 37
International life, accident, supplemental benefits businesses sold to Chubb \| Disposed of by Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sale price	$ 5,400
Gain (loss) on sale of business, pre-tax	1,700
Gain (loss) on sale of business, after-tax	$ 1,400

Earnings Per Share - Computatio

Earnings Per Share - Computation of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Earnings Per Share [Abstract]
Shareholders' net income	$ 1,267	$ 1,197	[1]
Shares:
Weighted average (in shares)	295,706	318,487
Common stock equivalents (in shares)	3,293	2,795
Total shares (in shares)	298,999	321,282
EPS, basic (in dollars per share)	$ 4.28	$ 3.76	[1]
EPS, effect of dilution (in dollars per share)	(0.04)	(0.03)
EPS, diluted (in dollars per share)	$ 4.24	$ 3.73	[1]

[1]Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.

Earnings Per Share - Outstandin

Earnings Per Share - Outstanding Employee Stock Options Not Included in the Computation of Diluted Earnings Per Share (Details) - shares shares in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Employee Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive options (in shares)	0.9	2.8

Earnings Per Share - Shares of

Earnings Per Share - Shares of Common Stock Held in Treasury (Details) - shares shares in Millions	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022
Earnings Per Share [Abstract]
Shares of common stock held in treasury	102.7	99.1	77.3

Debt - Outstanding Amounts of D

Debt - Outstanding Amounts of Debt and Finance Leases (Details) - USD ($)	Mar. 31, 2023	Jan. 15, 2023	Dec. 31, 2022
Short-term debt
Other, including finance leases	$ 36,000,000		$ 33,000,000
Total short-term debt	3,418,000,000		2,993,000,000	[1]
Long-term debt
Other, including finance leases	67,000,000		66,000,000
Total long-term debt	29,124,000,000		28,100,000,000	[1]
$17 million, 8.3% Notes due January 2023
Short-term debt
Current maturities	0		17,000,000
Long-term debt
Gross value	$ 17,000,000
Interest Rate	8.30%
$63 million, 7.65% Notes due March 2023
Short-term debt
Current maturities	$ 0		63,000,000
Long-term debt
Gross value	$ 63,000,000
Interest Rate	7.65%
$700 million, Floating Rate Notes due July 2023
Short-term debt
Current maturities	$ 700,000,000		700,000,000
Long-term debt
Gross value	700,000,000
$1,000 million, 3% Notes due July 2023
Short-term debt
Current maturities	996,000,000		994,000,000
Long-term debt
Gross value	$ 1,000,000,000
Interest Rate	3%
$1,187 million, 3.75% Notes due July 2023
Short-term debt
Current maturities	$ 1,187,000,000		1,186,000,000
Long-term debt
Gross value	$ 1,187,000,000
Interest Rate	3.75%
$500 million, 0.613% Notes due March 2024
Short-term debt
Current maturities	$ 499,000,000		0
Long-term debt
Long-term debt	0		499,000,000
Gross value	$ 500,000,000
Interest Rate	0.613%
$1,000 million, 3.500% Notes due June 2024
Long-term debt
Long-term debt	$ 992,000,000		990,000,000
Gross value	$ 1,000,000,000
Interest Rate	3.50%
$900 million, 3.250% Notes due April 2025 (1)
Long-term debt
Long-term debt	$ 878,000,000		872,000,000
Gross value	$ 900,000,000
Interest Rate	3.25%
$2,200 million, 4.125% Notes due November 2025
Long-term debt
Long-term debt	$ 2,195,000,000		2,195,000,000
Gross value	$ 2,200,000,000
Interest Rate	4.125%
$1,500 million, 4.500% Notes due February 2026
Long-term debt
Long-term debt	$ 1,503,000,000		1,503,000,000
Gross value	$ 1,500,000,000
Interest Rate	4.50%
$800 million, 1.250% Notes due March 2026
Long-term debt
Long-term debt	$ 797,000,000		797,000,000
Gross value	$ 800,000,000
Interest Rate	1.25%
$700 million, 5.685% Notes due March 2026
Long-term debt
Long-term debt	$ 697,000,000		0
Gross value	$ 700,000,000
Interest Rate	5.685%
$1,500 million, 3.400% Notes due March 2027
Long-term debt
Long-term debt	$ 1,440,000,000		1,436,000,000
Gross value	$ 1,500,000,000
Interest Rate	3.40%
$259 million, 7.875% Debentures due May 2027
Long-term debt
Long-term debt	$ 259,000,000		259,000,000
Gross value	$ 259,000,000
Interest Rate	7.875%
$600 million, 3.050% Notes due October 2027
Long-term debt
Long-term debt	$ 597,000,000		597,000,000
Gross value	$ 600,000,000
Interest Rate	3.05%
$3,800 million, 4.375% Notes due October 2028
Long-term debt
Long-term debt	$ 3,785,000,000		3,785,000,000
Gross value	$ 3,800,000,000
Interest Rate	4.375%
$1,500 million, 2.400% Notes due March 2030
Long-term debt
Long-term debt	$ 1,492,000,000		1,492,000,000
Gross value	$ 1,500,000,000
Interest Rate	2.40%
$1,500 million, 2.375% Notes due 2031
Long-term debt
Long-term debt	$ 1,398,000,000		1,380,000,000
Gross value	$ 1,500,000,000
Interest Rate	2.375%
$45 million, 8.080% Step Down Notes due January 2033 (2)
Long-term debt
Long-term debt	$ 45,000,000		45,000,000
Gross value	$ 45,000,000
Interest Rate	8.08%	8.08%
$800 million, 5.400% Notes due March 2033
Long-term debt
Long-term debt	$ 794,000,000		0
Gross value	$ 800,000,000
Interest Rate	5.40%
$190 million, 6.150% Notes due November 2036
Long-term debt
Long-term debt	$ 190,000,000		190,000,000
Gross value	$ 190,000,000
Interest Rate	6.15%
$2,200 million, 4.800% Notes due August 2038
Long-term debt
Long-term debt	$ 2,192,000,000		2,192,000,000
Gross value	$ 2,200,000,000
Interest Rate	4.80%
$750 million, 3.200% Notes due March 2040
Long-term debt
Long-term debt	$ 743,000,000		743,000,000
Gross value	$ 750,000,000
Interest Rate	3.20%
$121 million, 5.875% Notes due March 2041
Long-term debt
Long-term debt	$ 119,000,000		119,000,000
Gross value	$ 121,000,000
Interest Rate	5.875%
$448 million, 6.125% Notes due November 2041
Long-term debt
Long-term debt	$ 488,000,000		488,000,000
Gross value	$ 448,000,000
Interest Rate	6.125%
$317 million, 5.375% Notes due February 2042
Long-term debt
Long-term debt	$ 315,000,000		315,000,000
Gross value	$ 317,000,000
Interest Rate	5.375%
$1,500 million, 4.800% Notes due July 2046
Long-term debt
Long-term debt	$ 1,466,000,000		1,466,000,000
Gross value	$ 1,500,000,000
Interest Rate	4.80%
$1,000 million, 3.875% Notes due October 2047
Long-term debt
Long-term debt	$ 989,000,000		989,000,000
Gross value	$ 1,000,000,000
Interest Rate	3.875%
$3,000 million, 4.900% Notes due December 2048
Long-term debt
Long-term debt	$ 2,969,000,000		2,968,000,000
Gross value	$ 3,000,000,000
Interest Rate	4.90%
$1,250 million, 3.400% Notes due March 2050
Long-term debt
Long-term debt	$ 1,236,000,000		1,236,000,000
Gross value	$ 1,250,000,000
Interest Rate	3.40%
$1,500 million, 3.400% Notes due March 2051
Long-term debt
Long-term debt	$ 1,478,000,000		$ 1,478,000,000
Gross value	$ 1,500,000,000
Interest Rate	3.40%

[1]Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.

Debt - Debt Issuances and Redem

Debt - Debt Issuances and Redemptions (Details) $ in Millions	Mar. 07, 2023 USD ($)	Mar. 31, 2023
Senior Notes
Debt Instrument [Line Items]
Principal	$ 1,500
$700 million, 5.685% Notes due March 2026
Debt Instrument [Line Items]
Interest rate		5.685%
$700 million, 5.685% Notes due March 2026 \| Senior Notes
Debt Instrument [Line Items]
Principal	$ 700
Interest rate	5.685%
Net proceeds	$ 698
$700 million, 5.685% Notes due March 2026 \| Senior Notes \| Treasury rate
Debt Instrument [Line Items]
Redemption price discount, spread on variable rate	0.0020
$800 million, 5.400% Notes due March 2033
Debt Instrument [Line Items]
Interest rate		5.40%
$800 million, 5.400% Notes due March 2033 \| Senior Notes
Debt Instrument [Line Items]
Principal	$ 800
Interest rate	5.40%
Net proceeds	$ 796
$800 million, 5.400% Notes due March 2033 \| Senior Notes \| Treasury rate
Debt Instrument [Line Items]
Redemption price discount, spread on variable rate	0.0025

Debt - Narrative (Details)

Debt - Narrative (Details)	1 Months Ended		3 Months Ended
Debt - Narrative (Details)	Apr. 30, 2023 USD ($) revolvingCreditFacility position	Apr. 30, 2022 USD ($)	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)
Debt Instrument [Line Items]
Interest expense on long-term and short-term debt			$ 345,000,000	$ 314,000,000
Commercial Paper
Debt Instrument [Line Items]
Maximum borrowing capacity			5,000,000,000
Outstanding balances			0
Revolving credit agreements, April 2023
Debt Instrument [Line Items]
Number of revolving credit facilities \| revolvingCreditFacility	2
Revolving credit agreements, April 2023 \| Subsequent Event
Debt Instrument [Line Items]
Aggregate amount of options to increase commitments	$ 1,500,000,000
Maximum total commitment	$ 6,500,000,000
Number of participating banks \| position	21
Leverage ratio covenant	60%
Five-year Revolving Credit Agreement, Maturing April 2028 \| Subsequent Event
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 4,000,000,000
Credit agreement term	5 years
Credit agreement extension term	1 year
Five-year Revolving Credit Agreement, Maturing April 2028 \| Letter of Credit \| Subsequent Event
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 500,000,000
364-day Revolving Credit Agreement, Maturing April 2024 \| Subsequent Event
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 1,000,000,000
Credit agreement term	364 days
Credit facility, conversion to term loan, term	1 year
Revolving credit agreements, April 2022
Debt Instrument [Line Items]
Outstanding balances			$ 0
Revolving Credit And Letter Of Credit Facility Maturing April 2027
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 3,000,000,000
Credit agreement term		5 years
Revolving Credit Facility Maturing April 2025
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 1,000,000,000
Credit agreement term		3 years
364 Day Revolving Credit Agreement, Maturing April 2023
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 1,000,000,000
Credit agreement term		364 days

Common and Preferred Stock - Di

Common and Preferred Stock - Dividends (Details) - USD ($) $ / shares in Units, $ in Millions				3 Months Ended
	Apr. 26, 2023	Mar. 23, 2023	Mar. 24, 2022	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022
Subsequent Event [Line Items]
Common dividends declared (in dollars per share)				$ 1.23	$ 1.12	$ 1.12	$ 1.12	$ 1.12
Amount per share (in dollars per share)		$ 1.23	$ 1.12
Total amount paid		$ 368	$ 357	$ 368				$ 357	[1]
Subsequent Event
Subsequent Event [Line Items]
Common dividends declared (in dollars per share)	$ 1.23

[1]Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.

Common and Preferred Stock - Ac

Common and Preferred Stock - Accelerated Share Repurchase Agreements (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Accelerated Share Repurchases [Line Items]
Stock repurchased	$ 958	$ 1,334
Treasury Stock
Accelerated Share Repurchases [Line Items]
Stock repurchased	$ 958	1,334
Additional Paid-in Capital
Accelerated Share Repurchases [Line Items]
Stock repurchased		$ 0

Insurance and Contractholder _3

Insurance and Contractholder Liabilities - Account Balances (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022		Mar. 31, 2022	Dec. 31, 2021
Current
Market risk benefits, current	$ 48	$ 51
Unearned Premiums, Current	1,419	576
Current insurance and contractholder liabilities	7,166	5,409	[1]
Non-current
Market risk benefits, noncurrent	1,172	1,217
Unearned premiums, noncurrent	21	22
Non-current insurance and contractholder liabilities	11,790	11,976	[1]
Total
Market risk benfits	1,220	1,268		$ 1,558
Unearned premiums	1,440	598
Unearned premiums, including held for sale liabilities				1,030
Total				23,509
Insurance and contractholder liabilities classified as held for sale				(4,562)
Total insurance and contractholder liabilities	18,956	17,385		18,947
Unpaid claims classified as liabilities of business held for sale				400
Contractholder deposit funds classified as liabilities of business held for sale				400
Cigna Healthcare
Current
Unpaid claims and claim expenses, current	4,880	4,117
Future policy benefits, current	59	43
Contractholder deposit funds, current	12	14
Non-current
Unpaid claims and claim expenses, noncurrent	79	59
Future policy benefits, noncurrent	542	544
Contractholder deposit funds, noncurrent	151	157
Total
Unpaid claims and claim expenses	4,959	4,176		4,491	$ 4,261
Unpaid claims and claim expenses, including held for sale liabilities				4,491
Future policy benefits	601	587		681
Future policy benefits, including held for sale liabilities				681
Contractholder deposit funds	163	171		181
Other Operations
Current
Unpaid claims and claim expenses, current	97	107
Future policy benefits, current	290	150
Contractholder deposit funds, current	361	351
Non-current
Unpaid claims and claim expenses, noncurrent	175	177
Future policy benefits, noncurrent	3,341	3,442
Contractholder deposit funds, noncurrent	6,309	6,358
Total
Unpaid claims and claim expenses	272	284
Unpaid claims and claim expenses, including held for sale liabilities				744
Future policy benefits	3,631	3,592
Future policy benefits, including held for sale liabilities				7,981
Contractholder deposit funds	$ 6,670	$ 6,709		6,843	6,900
Future policy benefits classified as liabilities of business held for sale				$ 3,700	$ 3,800

[1]Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.

Insurance and Contractholder _4

Insurance and Contractholder Liabilities - Unpaid Claims and Claim Expenses - Cigna Healthcare - Activity (Details) - Cigna Healthcare - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Liability for Claims and Claims Adjustment Expense [Line Items]
Total of incurred but not reported liabilities plus expected claim development on reported claims, including reported claims in process	$ 4,600	$ 4,200
Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]
Beginning balance	4,176	4,261
Less: Reinsurance and other amounts recoverable	221	261
Beginning balance, net	3,955	4,000
Incurred costs related to:
Current year	9,041	8,024
Prior years	(144)	(276)
Total incurred	8,897	7,748
Paid costs related to:
Current year	5,316	4,634
Prior years	2,795	2,822
Total paid	8,111	7,456
Ending balance, net	4,741	4,292
Add: Reinsurance and other amounts recoverable	218	199
Ending balance	$ 4,959	$ 4,491

Insurance and Contractholder _5

Insurance and Contractholder Liabilities - Unpaid Claims and Claims Expenses - Cigna Healthcare - Variances in Incurred Costs Related to Prior Years' Unpaid Claims and Claims Expenses (Details) - Cigna Healthcare - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]
Favorable (unfavorable) variance, amount	$ 144	$ 276
Favorable (unfavorable) variance, percentage	0.50%	0.90%
Actual completion factors
Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]
Favorable (unfavorable) variance, amount	$ 1	$ 99
Favorable (unfavorable) variance, percentage	0%	0.30%
Medical cost trend
Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Abstract]
Favorable (unfavorable) variance, amount	$ 143	$ 177
Favorable (unfavorable) variance, percentage	0.50%	0.60%

Insurance and Contractholder _6

Insurance and Contractholder Liabilities - Future Policy Benefits - Interest Rates and Duration (Details)	Mar. 31, 2023	Mar. 31, 2022
Cigna Healthcare
Insurance and Contractholder Liabilities [Line Items]
Interest accretion rate	2.59%	2.64%
Current discount rate	5.29%	4.90%
Weighted average duration	8 years 18 days	7 years 5 months 12 days
Other Operations
Insurance and Contractholder Liabilities [Line Items]
Interest accretion rate	5.64%	5.64%
Current discount rate	4.95%	3.59%
Weighted average duration	11 years 8 months 12 days	13 years 10 months 24 days

Insurance and Contractholder _7

Insurance and Contractholder Liabilities - Future Policy Benefits - Present Value of Expected Premiums and Benefits (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]
Observable inputs from published spot rate curve term (in years)	30 years
Cigna Healthcare
Liability for Future Policy Benefit, Expected Net Premium [Roll Forward]
Beginning balance	$ 8,557	$ 9,314
Reversal of effect of beginning of period discount rate assumptions	1,537	(367)
Effect of assumption changes and actual variances from expected experience			$ 0	$ 0
Issuances and lapses	306	143
Net premiums collected	(326)	(310)
Interest and other	56	46
Ending balance at original discount rate	10,130	8,826
Effect of end of period discount rate assumptions	(1,312)	(376)
Ending balance	8,818	8,450	8,557	9,314
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]
Beginning balance	8,945	9,794
Reversal of effect of discount rate assumptions	1,611	(379)
Effect of assumption changes and actual variances from expected experience			0	0
Issuances and lapses	307	215
Benefit payments	(326)	(385)
Interest and other	58	52
Ending balance at original discount rate	10,595	9,297
Effect of discount rate assumptions	(1,378)	(392)
Ending balance	9,217	8,905	8,945	9,794
Liability for future policy benefits	399	455
Other	202	226
Future policy benefits	601	681	587
Undiscounted expected future gross premiums	17,600	13,500
Discounted expected future gross premiums	12,500	10,700
Undiscounted expected future policy benefits	12,800	11,200
Future policy benefit reserve, reinsurance recoverable	154	171
Other Operations
Liability for Future Policy Benefit, Expected Future Policy Benefit [Roll Forward]
Future policy benefits	3,631		3,592
Undiscounted expected future policy benefits	4,600	4,700
Future policy benefit reserve, reinsurance recoverable	1,000	1,200
Future policy benefits, DPL	392	384
Future policy benefit, excluding DPL	$ 3,200	3,900	$ 3,200	4,300
Future policy benefits classified as liabilities of business held for sale		$ 3,700		$ 3,800

Insurance and Contractholder _8

Insurance and Contractholder Liabilities - Contractholder Deposit Funds (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022	Dec. 31, 2021
Insurance and Contractholder Liabilities [Line Items]
Contractholder deposit fund liabilities, approximate percent reinsured externally	39%
Weighted average crediting rate	3.25%		3.18%
Net amount at risk	$ 3,200		$ 3,500
Cash surrender value	$ 2,800		$ 2,900
Minimum crediting rate	99%		99%
Percentage with cash values at more than 110% of guaranteed cash value	90%		90%
Policyholder Account Balance, above Guaranteed Minimum Crediting Rate, Range from 0051 to 0150
Insurance and Contractholder Liabilities [Line Items]
Policyholder account balance	$ 1,200		$ 1,200
Policyholder Account Balance, Above Guaranteed Minimum Crediting Rate, Based On Greater Of Guaranteed Minimum Cash Value Or Actual Cash Value
Insurance and Contractholder Liabilities [Line Items]
Policyholder account balance	1,700		1,700
Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400
Insurance and Contractholder Liabilities [Line Items]
Policyholder account balance	4,100		4,100
Policyholder Account Balance, at Guaranteed Minimum Crediting Rate
Insurance and Contractholder Liabilities [Line Items]
Policyholder account balance	$ 1,200		$ 1,200
Minimum \| Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400
Insurance and Contractholder Liabilities [Line Items]
Guaranteed minimum credit rating	3%		3%
Maximum \| Policyholder Account Balance, Guaranteed Minimum Crediting Rate, Range from 0300 To 0400
Insurance and Contractholder Liabilities [Line Items]
Guaranteed minimum credit rating	4%		4%
Cigna Healthcare
Insurance and Contractholder Liabilities [Line Items]
Contractholder deposit funds	$ 163	$ 171	$ 181
Other Operations
Insurance and Contractholder Liabilities [Line Items]
Contractholder deposit funds	$ 6,670	$ 6,709	$ 6,843	$ 6,900

Insurance and Contractholder _9

Insurance and Contractholder Liabilities - Summary of Market Risk Benefit (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Insurance Loss Reserves [Abstract]
Annuitization election period	30 days
Market Risk Benefit [Roll Forward]
Balance, beginning of year	$ 1,268	$ 1,824
Balance, beginning of year, before the effect of nonperformance risk (own credit risk)	1,379	1,949
Changes due to expected run-off	(6)	(19)
Changes due to capital markets versus expected	(41)	(271)
Changes due to policyholder behavior versus expected	6	(9)
Assumption changes	(33)	39
Balance, end of year, before the effect of changes in nonperformance risk (own credit risk)	1,305	1,689
Nonperformance risk (own credit risk), end of period	(85)	(131)
Balance, end of period	1,220	1,558
Reinsured market risk benefit, end of period	$ 1,301	$ 1,681

Insurance and Contractholder_10

Insurance and Contractholder Liabilities - Net Amount of Risk and Average Age of Contractholders (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Net Amount at Risk by Product and Guarantee [Line Items]
Net amount at risk	$ 85	$ 131
Variable Annuity
Net Amount at Risk by Product and Guarantee [Line Items]
Net amount at risk	$ 2,183	$ 1,892
Average attained age of contractholders (weighted by exposure)	75 years 4 months 24 days	76 years 4 months 24 days

Reinsurance - Reinsurance Recov

Reinsurance - Reinsurance Recoverables (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022
Ceded Credit Risk [Line Items]
Reinsurance recoverables	$ 4,251
Allowance for uncollectible reinsurance	(35)
Market risk benefits	1,301		$ 1,681
Total reinsurance recoverables	5,517
Other Current Assets
Ceded Credit Risk [Line Items]
Reinsurance recoverables	231
Fair value of collateral contractually required to meet or exceed carrying value of recoverable
Ceded Credit Risk [Line Items]
Reinsurance recoverables	709
Collateral provisions exist that may mitigate risk of credit loss
Ceded Credit Risk [Line Items]
Reinsurance recoverables	3,175
No collateral
Ceded Credit Risk [Line Items]
Reinsurance recoverables	367
Ongoing Operations
Ceded Credit Risk [Line Items]
Reinsurance recoverables	363
Ongoing Operations \| A- equivalent and higher current ratings
Ceded Credit Risk [Line Items]
Reinsurance recoverables	94
Ongoing Operations \| BBB- to BBB+ equivalent current credit ratings
Ceded Credit Risk [Line Items]
Reinsurance recoverables	59
Ongoing Operations \| Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	210
Ongoing Operations \| Fair value of collateral contractually required to meet or exceed carrying value of recoverable
Ceded Credit Risk [Line Items]
Reinsurance recoverables	142
Ongoing Operations \| Fair value of collateral contractually required to meet or exceed carrying value of recoverable \| A- equivalent and higher current ratings
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Ongoing Operations \| Fair value of collateral contractually required to meet or exceed carrying value of recoverable \| BBB- to BBB+ equivalent current credit ratings
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Ongoing Operations \| Fair value of collateral contractually required to meet or exceed carrying value of recoverable \| Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	142
Ongoing Operations \| Collateral provisions exist that may mitigate risk of credit loss
Ceded Credit Risk [Line Items]
Reinsurance recoverables	5
Ongoing Operations \| Collateral provisions exist that may mitigate risk of credit loss \| A- equivalent and higher current ratings
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Ongoing Operations \| Collateral provisions exist that may mitigate risk of credit loss \| BBB- to BBB+ equivalent current credit ratings
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Ongoing Operations \| Collateral provisions exist that may mitigate risk of credit loss \| Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	5
Ongoing Operations \| No collateral
Ceded Credit Risk [Line Items]
Reinsurance recoverables	216
Ongoing Operations \| No collateral \| A- equivalent and higher current ratings
Ceded Credit Risk [Line Items]
Reinsurance recoverables	94
Ongoing Operations \| No collateral \| BBB- to BBB+ equivalent current credit ratings
Ceded Credit Risk [Line Items]
Reinsurance recoverables	59
Ongoing Operations \| No collateral \| Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	63
Acquisition, disposition or run-off activities
Ceded Credit Risk [Line Items]
Reinsurance recoverables	3,888
Acquisition, disposition or run-off activities \| BBB+ equivalent and higher current ratings \| Lincoln National Life and Lincoln Life & Annuity of New York
Ceded Credit Risk [Line Items]
Reinsurance recoverables	2,750
Acquisition, disposition or run-off activities \| BBB+ equivalent and higher current ratings \| Empower Annuity Insurance Company
Ceded Credit Risk [Line Items]
Reinsurance recoverables	133
Acquisition, disposition or run-off activities \| BBB+ equivalent and higher current ratings \| Prudential Insurance Company of America
Ceded Credit Risk [Line Items]
Reinsurance recoverables	380
Acquisition, disposition or run-off activities \| BBB+ equivalent and higher current ratings \| Life Insurance Company of North America
Ceded Credit Risk [Line Items]
Reinsurance recoverables	386
Acquisition, disposition or run-off activities \| BBB+ equivalent and higher current ratings \| Other
Ceded Credit Risk [Line Items]
Reinsurance recoverables	227
Acquisition, disposition or run-off activities \| Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	12
Acquisition, disposition or run-off activities \| Fair value of collateral contractually required to meet or exceed carrying value of recoverable
Ceded Credit Risk [Line Items]
Reinsurance recoverables	567
Acquisition, disposition or run-off activities \| Fair value of collateral contractually required to meet or exceed carrying value of recoverable \| BBB+ equivalent and higher current ratings \| Lincoln National Life and Lincoln Life & Annuity of New York
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities \| Fair value of collateral contractually required to meet or exceed carrying value of recoverable \| BBB+ equivalent and higher current ratings \| Empower Annuity Insurance Company
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities \| Fair value of collateral contractually required to meet or exceed carrying value of recoverable \| BBB+ equivalent and higher current ratings \| Prudential Insurance Company of America
Ceded Credit Risk [Line Items]
Reinsurance recoverables	380
Acquisition, disposition or run-off activities \| Fair value of collateral contractually required to meet or exceed carrying value of recoverable \| BBB+ equivalent and higher current ratings \| Life Insurance Company of North America
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities \| Fair value of collateral contractually required to meet or exceed carrying value of recoverable \| BBB+ equivalent and higher current ratings \| Other
Ceded Credit Risk [Line Items]
Reinsurance recoverables	187
Acquisition, disposition or run-off activities \| Fair value of collateral contractually required to meet or exceed carrying value of recoverable \| Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities \| Collateral provisions exist that may mitigate risk of credit loss
Ceded Credit Risk [Line Items]
Reinsurance recoverables	3,170
Acquisition, disposition or run-off activities \| Collateral provisions exist that may mitigate risk of credit loss \| BBB+ equivalent and higher current ratings \| Lincoln National Life and Lincoln Life & Annuity of New York
Ceded Credit Risk [Line Items]
Reinsurance recoverables	2,750
Acquisition, disposition or run-off activities \| Collateral provisions exist that may mitigate risk of credit loss \| BBB+ equivalent and higher current ratings \| Empower Annuity Insurance Company
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities \| Collateral provisions exist that may mitigate risk of credit loss \| BBB+ equivalent and higher current ratings \| Prudential Insurance Company of America
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities \| Collateral provisions exist that may mitigate risk of credit loss \| BBB+ equivalent and higher current ratings \| Life Insurance Company of North America
Ceded Credit Risk [Line Items]
Reinsurance recoverables	386
Acquisition, disposition or run-off activities \| Collateral provisions exist that may mitigate risk of credit loss \| BBB+ equivalent and higher current ratings \| Other
Ceded Credit Risk [Line Items]
Reinsurance recoverables	25
Acquisition, disposition or run-off activities \| Collateral provisions exist that may mitigate risk of credit loss \| Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	9
Acquisition, disposition or run-off activities \| No collateral
Ceded Credit Risk [Line Items]
Reinsurance recoverables	151
Acquisition, disposition or run-off activities \| No collateral \| BBB+ equivalent and higher current ratings \| Lincoln National Life and Lincoln Life & Annuity of New York
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities \| No collateral \| BBB+ equivalent and higher current ratings \| Empower Annuity Insurance Company
Ceded Credit Risk [Line Items]
Reinsurance recoverables	133
Acquisition, disposition or run-off activities \| No collateral \| BBB+ equivalent and higher current ratings \| Prudential Insurance Company of America
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities \| No collateral \| BBB+ equivalent and higher current ratings \| Life Insurance Company of North America
Ceded Credit Risk [Line Items]
Reinsurance recoverables	0
Acquisition, disposition or run-off activities \| No collateral \| BBB+ equivalent and higher current ratings \| Other
Ceded Credit Risk [Line Items]
Reinsurance recoverables	15
Acquisition, disposition or run-off activities \| No collateral \| Not rated
Ceded Credit Risk [Line Items]
Reinsurance recoverables	$ 3
Variable Annuity
Ceded Credit Risk [Line Items]
Market risk benefits		$ 1,400
Variable Annuity \| GMDB
Ceded Credit Risk [Line Items]
Market risk benefits		$ 711

Reinsurance - Effective Exit of

Reinsurance - Effective Exit of Variable Annuity Reinsurance Business (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Ceded Credit Risk [Line Items]
Market risk benefits	$ 1,301	$ 1,681
Variable Annuity
Ceded Credit Risk [Line Items]
Impact of non-performance risk
Berkshire \| Secured \| Market risk benefits reinsurance recoverable, including IBNR and outstanding claims, less premiums due \| Collateralization risk
Ceded Credit Risk [Line Items]
Concentration percentage	90%
Liberty Re (Bermuda) Ltd. \| Secured \| Market risk benefits reinsurance recoverable, including IBNR and outstanding claims, less premiums due \| Collateralization risk
Ceded Credit Risk [Line Items]
Concentration percentage	100%
SCOR SE \| Secured \| Market risk benefits reinsurance recoverable, including IBNR and outstanding claims, less premiums due \| Collateralization risk
Ceded Credit Risk [Line Items]
Concentration percentage	70%
Variable Annuity
Ceded Credit Risk [Line Items]
Market risk benefits reinsurance recoverable, including IBNR and outstanding claims, less premiums due	$ 1,323		$ 1,398
Market risk benefits			1,400
Incurred but not yet paid and outstanding claims	25		27
Premiums due	$ 3		3
Variable Annuity \| Berkshire
Ceded Credit Risk [Line Items]
Percent of future claim payments reinsured	100%
Remaining overall limit under reinsurance agreement	$ 3,100
Market risk benefits reinsurance recoverable, including IBNR and outstanding claims, less premiums due	1,043		1,116
Variable Annuity \| Sun Life Assurance Company of Canada
Ceded Credit Risk [Line Items]
Market risk benefits reinsurance recoverable, including IBNR and outstanding claims, less premiums due	117		115
Variable Annuity \| Liberty Re (Bermuda) Ltd.
Ceded Credit Risk [Line Items]
Market risk benefits reinsurance recoverable, including IBNR and outstanding claims, less premiums due	128		128
Variable Annuity \| SCOR SE
Ceded Credit Risk [Line Items]
Market risk benefits reinsurance recoverable, including IBNR and outstanding claims, less premiums due	$ 35		$ 39

Investments - Investments by Ca

Investments - Investments by Category (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Current
Investments per Consolidated Balance Sheets	$ 914	$ 905	[1]
Long-term
Investments per Consolidated Balance Sheets	19,010	16,288	[1]
Total
Investments per Consolidated Balance Sheets	19,924	17,193
Debt securities
Current
Investments per Consolidated Balance Sheets	616	654
Long-term
Investments per Consolidated Balance Sheets	9,293	9,218
Total
Investments per Consolidated Balance Sheets	9,909	9,872
Equity securities
Current
Investments per Consolidated Balance Sheets	51	45
Long-term
Investments per Consolidated Balance Sheets	3,069	577
Total
Investments per Consolidated Balance Sheets	3,120	622
Commercial mortgage loans
Current
Investments per Consolidated Balance Sheets	106	67
Long-term
Investments per Consolidated Balance Sheets	1,501	1,547
Total
Investments per Consolidated Balance Sheets	1,607	1,614
Policy loans
Current
Investments per Consolidated Balance Sheets	0	0
Long-term
Investments per Consolidated Balance Sheets	1,211	1,218
Total
Investments per Consolidated Balance Sheets	1,211	1,218
Other long-term investments
Current
Investments per Consolidated Balance Sheets	0	0
Long-term
Investments per Consolidated Balance Sheets	3,936	3,728
Total
Investments per Consolidated Balance Sheets	3,936	3,728
Short-term investments
Current
Investments per Consolidated Balance Sheets	141	139
Long-term
Investments per Consolidated Balance Sheets	0	0
Total
Investments per Consolidated Balance Sheets	$ 141	$ 139

[1]Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.

Investments - Debt Securities b

Investments - Debt Securities by Contractual Maturity Periods (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Amortized Cost
Due in one year or less	$ 638
Due after one year through five years	3,972
Due after five years through ten years	3,227
Due after ten years	2,450
Mortgage and other asset-backed securities	381
Total	10,668	$ 10,842
Fair Value
Due in one year or less	630
Due after one year through five years	3,752
Due after five years through ten years	2,915
Due after ten years	2,268
Mortgage and other asset-backed securities	344
Total	$ 9,909	$ 9,872

Investments - Gross Unrealized

Investments - Gross Unrealized Appreciation (Depreciation) on Debt Securities (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	$ 10,668	$ 10,842
Allowance for Credit Loss	(41)	(44)
Unrealized Appreciation	170	133
Unrealized Depreciation	(888)	(1,059)
Fair Value	9,909	9,872
Federal government and agency
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	276	292
Allowance for Credit Loss	0	0
Unrealized Appreciation	29	32
Unrealized Depreciation	(8)	(12)
Fair Value	297	312
State and local government
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	42	43
Allowance for Credit Loss	0	0
Unrealized Appreciation	0	0
Unrealized Depreciation	(1)	(2)
Fair Value	41	41
Foreign government
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	373	375
Allowance for Credit Loss	0	0
Unrealized Appreciation	16	11
Unrealized Depreciation	(18)	(21)
Fair Value	371	365
Corporate
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	9,596	9,742
Allowance for Credit Loss	(41)	(44)
Unrealized Appreciation	124	89
Unrealized Depreciation	(823)	(981)
Fair Value	8,856	8,806
Mortgage and other asset-backed
Debt Securities, Available-for-sale [Line Items]
Amortized Cost	381	390
Allowance for Credit Loss	0	0
Unrealized Appreciation	1	1
Unrealized Depreciation	(38)	(43)
Fair Value	$ 344	$ 348

Investments - Summary of Debt S

Investments - Summary of Debt Securities with a Decline in Fair Value (Details) $ in Millions	Mar. 31, 2023 USD ($) position	Dec. 31, 2022 USD ($) position
Total
Fair Value	$ 7,433	$ 7,901
Total Amortized Cost	8,321	8,960
Unrealized Depreciation	$ (888)	$ (1,059)
Number of Issues \| position	3,760	3,777
Investment grade \| Debt securities
One year or less
Fair Value	$ 3,176	$ 5,533
Amortized Cost	3,362	6,127
Unrealized Depreciation	$ (186)	$ (594)
Number of Issues \| position	1,019	1,659
More than one year
Fair Value	$ 3,222	$ 1,151
Amortized Cost	3,808	1,487
Unrealized Depreciation	$ (586)	$ (336)
Number of Issues \| position	1,035	462
Below investment grade \| Debt securities
One year or less
Fair Value	$ 353	$ 887
Amortized Cost	371	964
Unrealized Depreciation	$ (18)	$ (77)
Number of Issues \| position	936	1,287
More than one year
Fair Value	$ 682	$ 330
Amortized Cost	780	382
Unrealized Depreciation	$ (98)	$ (52)
Number of Issues \| position	770	369

Investments - Equity Security I

Investments - Equity Security Investments (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	[1]	Dec. 31, 2022
Cost
Equity securities with readily determinable fair values	$ 680			$ 673
Equity securities with no readily determinable fair value	2,926			380
Total	3,606			1,053
Carrying Value
Equity securities with readily determinable fair values	91			138
Equity securities with no readily determinable fair value	3,029			484
Total	3,120			$ 622
Other Commitments [Line Items]
Amount funded	$ 2,794	$ 1,246
Equity Securities FV NI \| Product Concentration Risk \| Health Care Sector
Other Commitments [Line Items]
Concentration percentage	95%

[1]Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.

Investments - Summary of the Cr

Investments - Summary of the Credit Risk Profile of the Commercial Mortgage Loan Portfolio (Details) - Real Estate Loan - Commercial Portfolio Segment $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Schedule of Investments [Line Items]
Carrying value, after allowance for credit loss	$ 1,607	$ 1,614
Weighted Average
Schedule of Investments [Line Items]
Average Debt Service Coverage Ratio	1.89	1.89
Average Loan-to-Value Ratio	60%	60%
Below 60%
Schedule of Investments [Line Items]
Carrying value, after allowance for credit loss	$ 912	$ 901
Below 60% \| Weighted Average
Schedule of Investments [Line Items]
Average Debt Service Coverage Ratio	2.11	2.12
60% to 79%
Schedule of Investments [Line Items]
Carrying value, after allowance for credit loss	$ 504	$ 564
60% to 79% \| Weighted Average
Schedule of Investments [Line Items]
Average Debt Service Coverage Ratio	1.73	1.73
80% to 100%
Schedule of Investments [Line Items]
Carrying value, after allowance for credit loss	$ 191	$ 149
80% to 100% \| Weighted Average
Schedule of Investments [Line Items]
Average Debt Service Coverage Ratio	1.32	1.17

Investments - Carrying Values o

Investments - Carrying Values of Other Long-Term Investments (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Schedule of Investments [Line Items]
Other long-term investments	$ 3,936	$ 3,728
Real estate investments
Schedule of Investments [Line Items]
Other long-term investments	1,434	1,319
Securities partnerships
Schedule of Investments [Line Items]
Other long-term investments	2,259	2,166
Other
Schedule of Investments [Line Items]
Other long-term investments	$ 243	$ 243

Investments - Components of Net

Investments - Components of Net Investment Income (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Net Investment Income [Line Items]
Net investment income	$ 277	$ 414	[1]

[1]Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.

Investments - Realized Gains an

Investments - Realized Gains and Losses on Investments (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Investments [Abstract]
Net realized investment (losses), excluding credit loss expense and asset write-downs	$ (51)	$ (322)
Credit loss recoveries	3	0
Other investment asset write-downs	(8)	0
Net realized investment (losses), before income taxes	$ (56)	$ (322)	[1]

[1]Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.

Fair Value Measurements - Finan

Fair Value Measurements - Financial Assets and Liabilities Carried at Fair Value (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Financial assets at fair value:
Equity securities	$ 91	$ 138
Recurring
Financial assets at fair value:
Debt Securities	9,909	9,872
Equity securities	91	138
Short-term investments	141	139
Recurring \| Forwards, swaps, options
Financial assets at fair value:
Derivative assets	207	231
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring
Financial assets at fair value:
Debt Securities	151	147
Equity securities	6	6
Short-term investments	0	0
Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring \| Forwards, swaps, options
Financial assets at fair value:
Derivative assets	0	0
Significant Other Observable Inputs (Level 2) \| Recurring
Financial assets at fair value:
Debt Securities	9,288	9,278
Equity securities	84	132
Short-term investments	141	139
Significant Other Observable Inputs (Level 2) \| Recurring \| Forwards, swaps, options
Financial assets at fair value:
Derivative assets	206	230
Significant Unobservable Inputs (Level 3) \| Recurring
Financial assets at fair value:
Debt Securities	470	447
Equity securities	1	0
Short-term investments	0	0
Significant Unobservable Inputs (Level 3) \| Recurring \| Forwards, swaps, options
Financial assets at fair value:
Derivative assets	1	1
Federal government and agency \| Recurring
Financial assets at fair value:
Debt Securities	297	312
Federal government and agency \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring
Financial assets at fair value:
Debt Securities	151	147
Federal government and agency \| Significant Other Observable Inputs (Level 2) \| Recurring
Financial assets at fair value:
Debt Securities	146	165
Federal government and agency \| Significant Unobservable Inputs (Level 3) \| Recurring
Financial assets at fair value:
Debt Securities	0	0
State and local government \| Recurring
Financial assets at fair value:
Debt Securities	41	41
State and local government \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring
Financial assets at fair value:
Debt Securities	0	0
State and local government \| Significant Other Observable Inputs (Level 2) \| Recurring
Financial assets at fair value:
Debt Securities	41	41
State and local government \| Significant Unobservable Inputs (Level 3) \| Recurring
Financial assets at fair value:
Debt Securities	0	0
Foreign government \| Recurring
Financial assets at fair value:
Debt Securities	371	365
Foreign government \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring
Financial assets at fair value:
Debt Securities	0	0
Foreign government \| Significant Other Observable Inputs (Level 2) \| Recurring
Financial assets at fair value:
Debt Securities	371	365
Foreign government \| Significant Unobservable Inputs (Level 3) \| Recurring
Financial assets at fair value:
Debt Securities	0	0
Corporate \| Recurring
Financial assets at fair value:
Debt Securities	8,856	8,806
Corporate \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring
Financial assets at fair value:
Debt Securities	0	0
Corporate \| Significant Other Observable Inputs (Level 2) \| Recurring
Financial assets at fair value:
Debt Securities	8,421	8,394
Corporate \| Significant Unobservable Inputs (Level 3) \| Recurring
Financial assets at fair value:
Debt Securities	435	412
Mortgage and other asset-backed \| Recurring
Financial assets at fair value:
Debt Securities	344	348
Mortgage and other asset-backed \| Quoted Prices in Active Markets for Identical Assets (Level 1) \| Recurring
Financial assets at fair value:
Debt Securities	0	0
Mortgage and other asset-backed \| Significant Other Observable Inputs (Level 2) \| Recurring
Financial assets at fair value:
Debt Securities	309	313
Mortgage and other asset-backed \| Significant Unobservable Inputs (Level 3) \| Recurring
Financial assets at fair value:
Debt Securities	$ 35	$ 35

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) - Separate Account Assets - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Separate accounts assets classified in Level 3, period increase (decrease), including transfers in and out of Level 3
Recurring \| Securities partnerships
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Expected liquidation period after inception	10 years

Fair Value Measurements - Quant

Fair Value Measurements - Quantitative Information About Unobservable Inputs (Details) - Recurring - Significant Unobservable Inputs (Level 3) $ in Millions	Mar. 31, 2023 USD ($)	Dec. 31, 2022 USD ($)
Debt securities
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value	$ 470	$ 447
Corporate and government debt securities \| Securities Priced by the Company
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value	$ 433	$ 412
Corporate and government debt securities \| Securities Priced by the Company \| Minimum \| Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment	0.0060	0.0060
Corporate and government debt securities \| Securities Priced by the Company \| Maximum \| Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment	0.1060	0.1060
Corporate and government debt securities \| Securities Priced by the Company \| Weighted Average \| Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment	0.0300	0.0270
Mortgage and other asset-backed securities \| Securities Priced by the Company
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value	$ 35	$ 35
Mortgage and other asset-backed securities \| Securities Priced by the Company \| Minimum \| Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment	0.0105	0.0110
Mortgage and other asset-backed securities \| Securities Priced by the Company \| Maximum \| Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment	0.0520	0.0520
Mortgage and other asset-backed securities \| Securities Priced by the Company \| Weighted Average \| Liquidity
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Unobservable Adjustment	0.0310	0.0310
Other debt securities
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair Value	$ 2	$ 0

Fair Value Measurements - Chang

Fair Value Measurements - Changes in Level 3 Financial Assets and Financial Liabilities Carried at Fair Value (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Transfers into/(out of) Level 3
Change in unrealized gain or (loss) included in Other comprehensive loss for assets held at the end of the reporting period	$ 5	$ (13)
Debt and Equity Securities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	447
Beginning balance, including held for sale assets		796
Gains included in Shareholders' net income	1	12
Gains (losses) included in Other comprehensive loss	5	(15)
Gains (losses) required to adjust future policy benefits for settlement annuities	0	(12)
Purchases, sales and settlements
Purchases	4	49
Settlements	(9)	(81)
Total purchases, sales and settlements	(5)	(32)
Transfers into/(out of) Level 3
Transfers into Level 3	39	101
Transfers out of Level 3	(16)	(164)
Total transfers into/(out of) Level 3	23	(63)
Ending balance	471
Ending balance, including held for sale assets		686
Total gains included in Shareholders' net income attributable to instruments held at the reporting date	$ 1	$ 0

Fair Value Measurements - Fair

Fair Value Measurements - Fair Values of Separate Account Assets (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Guaranteed separate accounts	$ 562	$ 585
Non-guaranteed separate accounts	6,020	5,936
Subtotal	6,582	6,521
Non-guaranteed separate accounts priced at NAV as a practical expedient	758	757
Separate account assets	7,340	7,278	[1]
Pension Plans
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Non-guaranteed separate accounts	4,000	4,000
Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Guaranteed separate accounts	213	203
Non-guaranteed separate accounts	221	211
Subtotal	434	414
Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Guaranteed separate accounts	349	382
Non-guaranteed separate accounts	5,586	5,522
Subtotal	5,935	5,904
Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Guaranteed separate accounts	0	0
Non-guaranteed separate accounts	213	203
Subtotal	213	203
Significant Unobservable Inputs (Level 3) \| Pension Plans
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Non-guaranteed separate accounts	$ 200	$ 200

[1]Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information on Separate Account Assets Priced at Net Asset Value (Details) - Separate Account Assets - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Unfunded Commitments	$ 228
Recurring \| NAV
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair Value	758	$ 757
Securities partnerships
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Unfunded Commitments	228
Securities partnerships \| Recurring \| NAV
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair Value	467	451
Real estate funds
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Unfunded Commitments	$ 0
Real estate funds \| Minimum
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Redemption Notice Period	30 days
Real estate funds \| Maximum
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Redemption Notice Period	90 days
Real estate funds \| Recurring \| NAV
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair Value	$ 287	302
Hedge funds
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Unfunded Commitments	$ 0
Hedge funds \| Minimum
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Redemption Notice Period	30 days
Hedge funds \| Maximum
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Redemption Notice Period	90 days
Hedge funds \| Recurring \| NAV
Fair Value, Investments, Entities that Calculate Net Asset Value Per Share [Line Items]
Fair Value	$ 4	$ 4

Fair Value Measurements - Asset

Fair Value Measurements - Assets and Liabilities Measured at Fair Value under Certain Conditions (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Realized investment losses on assets measured at fair value under certain conditions, after-tax
Realized investment gains on equity securities with no readily determinable fair value

Fair Value Measurements - Fai_2

Fair Value Measurements - Fair Value Disclosures for Financial Instruments Not Carried at Fair Value (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Fair Value \| Significant Other Observable Inputs (Level 2)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long-term debt, including current maturities, excluding finance leases	$ 30,679	$ 28,653
Fair Value \| Significant Unobservable Inputs (Level 3)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Commercial mortgage loans	1,509	1,491
Carrying Value
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Commercial mortgage loans	1,607	1,614
Long-term debt, including current maturities, excluding finance leases	$ 32,439	$ 30,994

Variable Interest Entities (Det

Variable Interest Entities (Details) - entity	Mar. 31, 2023	Dec. 31, 2022
Variable Interest Entity, Primary Beneficiary
Variable Interest Entity [Line Items]
Number of VIEs	0	0

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Income (Loss) (Details) - USD ($) $ in Millions		3 Months Ended
		Mar. 31, 2023		Mar. 31, 2022
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	[2]	$ 44,688	[1]	$ 46,976
Other comprehensive loss, net of tax		(111)		(434)	[3]
Less: Net translation (loss) on foreign currencies attributable to noncontrolling interests		0		(2)	[3]
Shareholders other comprehensive income (loss), net of tax		(111)		(432)
Balance		44,518		46,145
Accumulated Other Comprehensive (Loss)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance	[2]	(1,658)		(1,068)
Shareholders other comprehensive income (loss), net of tax		(111)		(432)
Balance		(1,769)		(1,500)
Securities and Derivatives
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance		(332)		1,266
Other comprehensive income (loss) before reclassifications, before tax		252		(1,065)
Other comprehensive income (loss), before reclassifications, tax		(54)		231
Other comprehensive income (loss) before reclassifications, after-tax		198		(834)
Reclassification adjustment, tax		1		2
Net amounts reclassified from AOCI to net income		(4)		(9)
Shareholders other comprehensive income (loss), net of tax		194		(843)
Balance		(138)		423
Reclassification adjustment for (gains) included in Shareholders' net income (Net realized investment losses)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reclassification adjustment, before tax		(5)		(11)
AOCI, Liability For Future Policy Benefit And Market Risk Benefit, Instrument-Specific Credit Risk, Parent
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance		(256)		(765)
Shareholders other comprehensive income (loss), net of tax		(331)		459
Balance		(587)		(306)
AOCI, Liability for Future Policy Benefit, Parent
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other comprehensive income (loss) before reclassifications, before tax		(411)		584
Other comprehensive income (loss), before reclassifications, tax		101		(130)
Shareholders other comprehensive income (loss), net of tax		(310)		454
AOCI, Market Risk Benefit, Instrument-Specific Credit Risk, Parent
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other comprehensive income (loss) before reclassifications, before tax		(26)		6
Other comprehensive income (loss), before reclassifications, tax		5		(1)
Shareholders other comprehensive income (loss), net of tax		(21)		5
Translation of foreign currencies attributable to parent
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance		(154)		(233)
Shareholders other comprehensive income (loss), net of tax		16		(61)
Balance		(138)		(294)
Translation of foreign currencies including portion attributable to noncontrolling interest
Accumulated Other Comprehensive Income (Loss) [Line Items]
Other comprehensive income (loss) including temporary equity, before reclassifications, before tax		15		(60)
Other comprehensive income (loss) including temporary equity, before reclassifications, tax		1		(3)
Other comprehensive income (loss) including temporary equity, before reclassifications, after-tax		16		(63)
Translation of foreign currencies attributable to noncontrolling interest
Accumulated Other Comprehensive Income (Loss) [Line Items]
Less: Net translation (loss) on foreign currencies attributable to noncontrolling interests		0		(2)
Postretirement benefits liability
Accumulated Other Comprehensive Income (Loss) [Line Items]
Balance		(916)		(1,336)
Reclassification adjustment, tax		(3)		(3)
Net amounts reclassified from AOCI to net income		10		13
Shareholders other comprehensive income (loss), net of tax		10		13
Balance		(906)		(1,323)
Reclassification adjustment for amortization of net prior actuarial losses and prior service costs (Interest expense and other)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Reclassification adjustment, before tax		$ 13		$ 16

[1]Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.[2]Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements to the Consolidated Financial Statements for further information.[3]Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
Income Taxes - Narrative (Details) - USD ($) $ in Millions	Mar. 31, 2023	Mar. 31, 2022
Income Tax Disclosure [Abstract]
Consolidated effective tax rate	18.40%	22.70%
Deferred tax assets associated with unrealized investment losses	$ 255

Contingencies and Other Matte_2

Contingencies and Other Matters (Details)			1 Months Ended	3 Months Ended
Contingencies and Other Matters (Details)	Mar. 31, 2022 USD ($)	Apr. 19, 2016 claim	Mar. 31, 2016 USD ($)	Mar. 31, 2023 USD ($)	Mar. 08, 2023 expert
Express Scripts Litigation with Elevance \| Judicial Ruling \| Pricing Concessions
Commitments And Contingencies [Line Items]
Damages sought by Elevance	$ 14,800,000,000
Express Scripts Litigation with Elevance \| Pending Litigation
Commitments And Contingencies [Line Items]
Number of experts \| expert					4
Number of additional experts \| expert					2
Express Scripts Litigation with Elevance \| Pending Litigation \| Pricing Concessions Through Remaining Contract Term
Commitments And Contingencies [Line Items]
Damages sought by Elevance			$ 13,000,000,000
Express Scripts Litigation with Elevance \| Pending Litigation \| Pricing Concessions After Remaining Term of Agreement
Commitments And Contingencies [Line Items]
Damages sought by Elevance			1,800,000,000
Express Scripts Litigation with Elevance \| Pending Litigation \| Damages for Service Issues
Commitments And Contingencies [Line Items]
Damages sought by Elevance			$ 150,000,000
Express Scripts counterclaims against Elevance
Commitments And Contingencies [Line Items]
Number of counts dismissed \| claim		2
Number of counts \| claim		6
Indemnification obligations
Commitments And Contingencies [Line Items]
Liability for guarantees				$ 0
Retiree and Life Insurance Benefits \| Financial Guarantees
Commitments And Contingencies [Line Items]
Maximum guarantee exposure				420,000,000
Assets maintained by employers (minimum)				420,000,000
Liability for guarantees				$ 0

Segment Information - Summary o

Segment Information - Summary of Special Items (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Pre-tax
Integration and transaction-related costs, pre-tax	$ 1	$ 52
Total impact from special items	1	52
After-tax
Integration and transaction-related costs, after-tax	1	37
Total impact from special items	$ 1	$ 37

Segment Information - Summarize

Segment Information - Summarized Segment Financial Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Segment Reporting Information [Line Items]
Revenues from customers	$ 46,240	$ 43,592
Net investment income (loss)	277	414	[1]
TOTAL REVENUES	46,517	44,006	[1]
Net realized investment results from certain equity method investments	(38)	103
Adjusted revenues	46,479	44,109
Depreciation and amortization	749	717	[2]
Income before income taxes	1,601	1,567	[1]
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) loss attributable to noncontrolling interests	(43)	(17)
Net realized investment (gains) losses	18	425
Amortization of acquired intangible assets	459	458	[1]
Special items
Integration and transaction-related costs	1	52
Pre-tax adjusted income (loss) from operations	2,036	2,485
Evernorth Health Services
Segment Reporting Information [Line Items]
Revenues from customers	34,511	32,289
Cigna Healthcare
Segment Reporting Information [Line Items]
Revenues from customers	11,650	10,462
Other Operations
Segment Reporting Information [Line Items]
Revenues from customers	79	841
Operating Segments \| Evernorth Health Services
Segment Reporting Information [Line Items]
Net investment income (loss)	50	10
TOTAL REVENUES	36,179	33,586
Net realized investment results from certain equity method investments	0	0
Adjusted revenues	36,179	33,586
Income before income taxes	918	870
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) loss attributable to noncontrolling interests	(42)	(11)
Net realized investment (gains) losses	0	0
Amortization of acquired intangible assets	444	443
Special items
Integration and transaction-related costs	0	0
Pre-tax adjusted income (loss) from operations	1,320	1,302
Operating Segments \| Cigna Healthcare
Segment Reporting Information [Line Items]
Net investment income (loss)	143	266
TOTAL REVENUES	12,756	11,290
Net realized investment results from certain equity method investments	(38)	103
Adjusted revenues	12,718	11,393
Income before income taxes	1,077	877
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) loss attributable to noncontrolling interests	(1)	(1)
Net realized investment (gains) losses	24	406
Amortization of acquired intangible assets	15	15
Special items
Integration and transaction-related costs	0	0
Pre-tax adjusted income (loss) from operations	1,115	1,297
Operating Segments \| Other Operations
Segment Reporting Information [Line Items]
Net investment income (loss)	78	138
TOTAL REVENUES	157	979
Net realized investment results from certain equity method investments	0	0
Adjusted revenues	157	979
Income before income taxes	21	215
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) loss attributable to noncontrolling interests	0	(5)
Net realized investment (gains) losses	(6)	19
Amortization of acquired intangible assets	0	0
Special items
Integration and transaction-related costs	0	0
Pre-tax adjusted income (loss) from operations	15	229
Corporate and Eliminations
Segment Reporting Information [Line Items]
Net investment income (loss)	6	0
TOTAL REVENUES	(2,575)	(1,849)
Net realized investment results from certain equity method investments	0	0
Adjusted revenues	(2,575)	(1,849)
Income before income taxes	(415)	(395)
Special items
Pre-tax adjusted income (loss) from operations	(414)	(343)
Corporate
Segment Reporting Information [Line Items]
Revenues from customers	0	0
Pre-tax adjustments to reconcile to adjusted income from operations
(Income) loss attributable to noncontrolling interests	0	0
Net realized investment (gains) losses	0	0
Amortization of acquired intangible assets	0	0
Special items
Integration and transaction-related costs	1	52
Intersegment Eliminations
Segment Reporting Information [Line Items]
Revenues from customers	(2,581)	(1,849)
Intersegment Eliminations \| Evernorth Health Services
Segment Reporting Information [Line Items]
Revenues from customers	(1,618)	(1,287)
Intersegment Eliminations \| Cigna Healthcare
Segment Reporting Information [Line Items]
Revenues from customers	(963)	(562)
Intersegment Eliminations \| Other Operations
Segment Reporting Information [Line Items]
Revenues from customers	$ 0	$ 0

[1]Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.[2]Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.

Segment Information - Revenue f

Segment Information - Revenue from External Customers (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue from External Customer [Line Items]
Premiums	$ 11,025	$ 10,356	[1]
Total revenues from external customers	46,240	43,592
Intersegment Eliminations
Revenue from External Customer [Line Items]
Premiums	16	(2)
Total revenues from external customers	(2,581)	(1,849)
Operating Segments \| Divested International businesses
Revenue from External Customer [Line Items]
Premiums	0	763
Operating Segments \| Other
Revenue from External Customer [Line Items]
Premiums	79	69
Evernorth Health Services
Revenue from External Customer [Line Items]
Total revenues from external customers	34,511	32,289
Evernorth Health Services \| Intersegment Eliminations
Revenue from External Customer [Line Items]
Total revenues from external customers	(1,618)	(1,287)
Cigna Healthcare
Revenue from External Customer [Line Items]
Total revenues from external customers	11,650	10,462
Cigna Healthcare \| Intersegment Eliminations
Revenue from External Customer [Line Items]
Total revenues from external customers	(963)	(562)
Other Operations
Revenue from External Customer [Line Items]
Total revenues from external customers	79	841
Other Operations \| Intersegment Eliminations
Revenue from External Customer [Line Items]
Total revenues from external customers	0	0
Pharmacy revenues
Revenue from External Customer [Line Items]
Revenues	32,144	30,697	[1]
Pharmacy revenues \| Intersegment Eliminations
Revenue from External Customer [Line Items]
Revenues	(1,496)	(1,245)
Network revenues \| Operating Segments
Revenue from External Customer [Line Items]
Revenues	15,748	15,531
Home delivery and specialty revenues \| Operating Segments
Revenue from External Customer [Line Items]
Revenues	16,025	14,699
Other revenues \| Operating Segments
Revenue from External Customer [Line Items]
Revenues	1,867	1,712
Cigna Healthcare \| Cigna Healthcare \| Operating Segments
Revenue from External Customer [Line Items]
Premiums	10,930	9,526
Insured \| Cigna Healthcare \| Operating Segments
Revenue from External Customer [Line Items]
Premiums	4,080	3,720
Stop loss \| Cigna Healthcare \| Operating Segments
Revenue from External Customer [Line Items]
Premiums	1,503	1,325
Other Commercial Medical Products \| Cigna Healthcare \| Operating Segments
Revenue from External Customer [Line Items]
Premiums	368	360
Medicare Advantage \| Cigna Healthcare \| Operating Segments
Revenue from External Customer [Line Items]
Premiums	2,236	2,078
Medicare Part D \| Cigna Healthcare \| Operating Segments
Revenue from External Customer [Line Items]
Premiums	415	401
Short-duration (Individual and family plans) \| Cigna Healthcare \| Operating Segments
Revenue from External Customer [Line Items]
Premiums	1,208	611
Long-duration (Individual Medicare supplement and limited benefit health products) \| Cigna Healthcare \| Operating Segments
Revenue from External Customer [Line Items]
Premiums	334	329
Short-duration (Group medical insurance) \| Cigna Healthcare \| Operating Segments
Revenue from External Customer [Line Items]
Premiums	700	620
Long-duration (Individual private medical insurance) \| Cigna Healthcare \| Operating Segments
Revenue from External Customer [Line Items]
Premiums	86	82
Service
Revenue from External Customer [Line Items]
Revenues	3,071	2,539	[1]
Service \| Intersegment Eliminations
Revenue from External Customer [Line Items]
Revenues	(1,101)	(602)
Fees \| Evernorth Health Services \| Operating Segments
Revenue from External Customer [Line Items]
Revenues	2,499	1,624
Fees \| Cigna Healthcare \| Operating Segments
Revenue from External Customer [Line Items]
Revenues	1,606	1,496
Fees \| Other Operations \| Operating Segments
Revenue from External Customer [Line Items]
Revenues	1	5
Other revenues \| Operating Segments
Revenue from External Customer [Line Items]
Revenues	$ 66	$ 16

[1]Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.

Segment Information - Financial

Segment Information - Financial and Performance Guarantees (Details) - USD ($) $ in Billions	Mar. 31, 2023	Dec. 31, 2022
Pharmacy Benefits Management Services \| Guarantees
Loss Contingencies [Line Items]
Guarantee liability	$ 1.5	$ 1.3